<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32012925</article-id>
<article-id pub-id-type="pmc">7037267</article-id>
<article-id pub-id-type="doi">10.3390/ijms21030836</article-id>
<article-id pub-id-type="publisher-id">ijms-21-00836</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alpha-1 Antitrypsin—A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hunt</surname>
<given-names>Alison M.D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8331-7668</contrib-id>
<name>
<surname>Glasgow</surname>
<given-names>Arlene M.A.</given-names>
</name>
<xref ref-type="corresp" rid="c1-ijms-21-00836">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Humphreys</surname>
<given-names>Hilary</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2549-2569</contrib-id>
<name>
<surname>Greene</surname>
<given-names>Catherine M.</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-ijms-21-00836">Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin 9, Ireland</aff>
<author-notes>
<corresp id="c1-ijms-21-00836"><label>*</label>Correspondence: <email>arleneglasgow@rcsi.ie</email>; Tel.: +353-1809-3801</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<issue>3</issue>
<elocation-id>836</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Cystic fibrosis (CF) is an autosomal recessive genetic disorder arising from mutations to the cystic fibrosis transmembrane conductance regulator (<italic>CFTR</italic>) gene. Disruption to normal ion homeostasis in the airway results in impaired mucociliary clearance, leaving the lung more vulnerable to recurrent and chronic bacterial infections. The CF lung endures an excess of neutrophilic inflammation, and whilst neutrophil serine proteases are a crucial part of the innate host defence to infection, a surplus of neutrophil elastase (NE) is understood to create a net destructive effect. Alpha-1 antitrypsin (A1AT) is a key antiprotease in the control of NE protease activity but is ineffective in the CF lung due to the huge imbalance of NE levels. Therapeutic strategies to boost levels of protective antiproteases such as A1AT in the lung remain an attractive research strategy to limit the damage from excess protease activity. microRNAs are small non-coding RNA molecules that bind specific cognate sequences to inhibit expression of target mRNAs. The inhibition of miRNAs which target the <italic>SERPINA1</italic> (A1AT-encoding gene) mRNA represents a novel therapeutic approach for CF inflammation. This could involve the delivery of antagomirs that bind and sequester the target miRNA, or target site blockers that bind miRNA recognition elements within the target mRNA to prevent miRNA interaction. Therefore, miRNA targeted therapies offer an alternative strategy to drive endogenous A1AT production and thus supplement the antiprotease shield of the CF lung.</p>
</abstract>
<kwd-group>
<kwd>cystic fibrosis</kwd>
<kwd>neutrophil elastase</kwd>
<kwd>antiproteases</kwd>
<kwd>alpha-1 antitrypsin</kwd>
<kwd>microRNA</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-21-00836" sec-type="intro">
<title>1. Introduction</title>
<p>Cystic fibrosis (CF) is a complex inherited disorder that affects numerous organ systems, principally the respiratory and gastro-intestinal tracts [<xref ref-type="bibr" rid="B1-ijms-21-00836">1</xref>]. It is inherited in an autosomal recessive manner, where individuals that are heterozygous for a mutant cystic fibrosis transmembrane conductance regulator allele (<italic>CFTR</italic>) are termed carriers of the disease and are largely asymptomatic; whereas those who carry two mutant <italic>CFTR</italic> alleles have the disease. CF is the most common inherited lethal disorder in the Western population, with up to 30,000 individuals in the United States and 27,000 in Europe having the disease [<xref ref-type="bibr" rid="B2-ijms-21-00836">2</xref>].</p>
<sec id="sec1dot1-ijms-21-00836">
<title>1.1. The CFTR Gene and Protein</title>
<p>The <italic>CTFR</italic> gene is located on the long arm of chromosome 7 at position q31.2. It is approximately 250 kb in length and it contains 27 exons [<xref ref-type="bibr" rid="B3-ijms-21-00836">3</xref>]. The CFTR protein is a 1480 amino acid, membrane-bound ion channel which is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily of transporters [<xref ref-type="bibr" rid="B4-ijms-21-00836">4</xref>]. These proteins utilise the energy from ATP hydrolysis to drive the transport of various molecules across the cell membrane, e.g., CFTR facilitates the transport of chloride and bicarbonate ions [<xref ref-type="bibr" rid="B5-ijms-21-00836">5</xref>]. CFTR works in conjunction with other ion channels including the epithelial sodium channel (ENaC) and the calcium activated chloride channel, anoctamin 1 (ANO1), to regulate fluid movement through the epithelium [<xref ref-type="bibr" rid="B6-ijms-21-00836">6</xref>,<xref ref-type="bibr" rid="B7-ijms-21-00836">7</xref>]. CFTR is therefore a critical regulator of the volume, pH and mucus viscosity of the airway surface liquid [<xref ref-type="bibr" rid="B8-ijms-21-00836">8</xref>]. </p>
<p>Mutations in the <italic>CFTR</italic> gene lead to a dysfunctional CFTR protein. Currently over 2000 mutations have been described and are divided into seven classes (I to VII) according to their effect on CFTR and therefore the disease severity and presentation [<xref ref-type="bibr" rid="B9-ijms-21-00836">9</xref>]. Classes I to VI result in defective protein synthesis, impaired protein trafficking, reduced channel open probability, defective ion channel conductance, decreased membrane expression of CFTR, or decreased CFTR stability, respectively. Class VII is a complete absence of <italic>CFTR</italic> mRNA caused by very large deletions [<xref ref-type="bibr" rid="B10-ijms-21-00836">10</xref>]. The most common CFTR mutation is a three base-pair deletion of phenylalanine 508 (F508del) (Class II) and affects 85% of patients [<xref ref-type="bibr" rid="B10-ijms-21-00836">10</xref>]. </p>
</sec>
<sec id="sec1dot2-ijms-21-00836">
<title>1.2. CF Disease Presentation</title>
<p>The CFTR protein is expressed in exocrine tissues throughout the body, creating a multisystem presentation of the disease. A defective CFTR protein leads to diminished anion secretions across secretory epithelia, resulting in thickened and viscous mucus in the lung, gastro-intestinal tract and the reproductive system [<xref ref-type="bibr" rid="B11-ijms-21-00836">11</xref>]. Although CF is a systemic disease, progressive lung disease remains to be the major contributor of morbidity and mortality to most patients [<xref ref-type="bibr" rid="B11-ijms-21-00836">11</xref>].</p>
<p>CF lung disease is attributable to a combination of impaired mucociliary clearance as a consequence of abnormally viscous secretions and by a failure of the innate immune system to clear infections. These factors make the CF airway susceptible to primary and recurrent bacterial infections, blockage, lung inflammation and chronic bacterial infections [<xref ref-type="bibr" rid="B11-ijms-21-00836">11</xref>].</p>
<p>Chronic and/or recurrent lung infections leave the lung in a continued pro-inflammatory state, resulting in the development of bronchiectasis. Bronchiectatic airways lose their cartilaginous support, become ‘floppy’ and collapse easily, further impairing mucociliary clearance and predisposing the lung to infection [<xref ref-type="bibr" rid="B11-ijms-21-00836">11</xref>]. Over time, chronic mucus plugging and infection damage the airways to such an extent that progressive respiratory failure ensues [<xref ref-type="bibr" rid="B12-ijms-21-00836">12</xref>]. </p>
<p>Numerous advances have been made in the treatment of CF, especially in the clearance of airway infections. However, with the emergence of multi-drug resistant pathogens, fresh challenges now lie ahead in the treatment and management of CF and there is a need for additional therapies for CF lung infection [<xref ref-type="bibr" rid="B13-ijms-21-00836">13</xref>].</p>
</sec>
</sec>
<sec id="sec2-ijms-21-00836">
<title>2. Cells of the Innate Immune System</title>
<p>Following pathogen recognition, immune cells are rapidly recruited towards the site of infection in response to the release of pro-inflammatory cytokines and chemokines [<xref ref-type="bibr" rid="B14-ijms-21-00836">14</xref>]. Phagocytosis of microbes is highly reliant on neutrophils and macrophages whereas antigen presentation to the adaptive immune system is reliant on macrophages and dendritic cells [<xref ref-type="bibr" rid="B14-ijms-21-00836">14</xref>]. Monocyte/macrophage and neutrophil dysfunction are both known to be implicated in CF.</p>
<sec id="sec2dot1-ijms-21-00836">
<title>2.1. Monocytes and Macrophages in CF </title>
<p>The notion that CF macrophages are defective has been well established through numerous studies over the past couple of decades. It was found that reduced CFTR expression or CFTR inhibition on macrophages results in hypersecretion of pro-inflammatory cytokines [<xref ref-type="bibr" rid="B15-ijms-21-00836">15</xref>]. This may in part be due to the increased expression of pattern recognition receptors (PRRs), such as Toll-like receptor 4 (TLR4) on CF macrophages [<xref ref-type="bibr" rid="B16-ijms-21-00836">16</xref>], but it may also be due to the defective autophagy of PRRs serving to further stimulate the pro-inflammatory pathways [<xref ref-type="bibr" rid="B17-ijms-21-00836">17</xref>]. Additionally, inflammatory mediators present in the CF lung, including proteases, may chronically activate macrophage PRRs (and also in other cell types), serving to optimise pathogen recognition whilst promoting inflammation [<xref ref-type="bibr" rid="B18-ijms-21-00836">18</xref>].</p>
<p>Human and animal studies have also suggested that CF macrophages are intrinsically hyper-inflammatory, with increased production of pro-inflammatory cytokines in response to exposure to various bacteria, pathogen-associated molecular patterns (PAMPs) and inflammatory mediators [<xref ref-type="bibr" rid="B17-ijms-21-00836">17</xref>,<xref ref-type="bibr" rid="B19-ijms-21-00836">19</xref>]. In addition, studies have shown that negative regulation of pro-inflammatory pathways is impaired in CF macrophages, further establishing a chronically inflamed lung environment [<xref ref-type="bibr" rid="B18-ijms-21-00836">18</xref>].</p>
<p>Adding to their hyper-inflammatory qualities, CF macrophages have been shown to have defective bacterial clearance capabilities. Reduced CFTR expression in monocytes impairs β-1 and β-2 integrin-mediated adhesion and chemotaxis, preventing adequate monocyte transmigration to the site of infection [<xref ref-type="bibr" rid="B20-ijms-21-00836">20</xref>]. Additionally, diminished CFTR expression on CF macrophages has been shown to hinder their ability to kill phagocytosed bacteria intracellularly. In the CF lung, bacterial clearance capabilities of monocytes or macrophages are further impaired [<xref ref-type="bibr" rid="B15-ijms-21-00836">15</xref>]. It was proposed that the absence of CFTR protein is associated with the alkalisation of the phagosome lumen, which impairs <italic>P. aeruginosa</italic> killing [<xref ref-type="bibr" rid="B21-ijms-21-00836">21</xref>]. The CF lung has a high protease burden and proteases are known to cleave cell-surface immune receptors [<xref ref-type="bibr" rid="B22-ijms-21-00836">22</xref>]. As a result, the ability of a monocyte or macrophage to recognise and clear infections is impaired [<xref ref-type="bibr" rid="B18-ijms-21-00836">18</xref>]. Furthermore, cleavage of surface immune receptors has negative consequences for the adaptive immune response to infection [<xref ref-type="bibr" rid="B18-ijms-21-00836">18</xref>]. Lastly, it is speculated that CF macrophages may be defective at releasing bactericidal mediators, such as carbon monoxide and antimicrobial enzymes, further impairing bacterial clearance [<xref ref-type="bibr" rid="B18-ijms-21-00836">18</xref>].</p>
</sec>
<sec id="sec2dot2-ijms-21-00836">
<title>2.2. Neutrophils in CF</title>
<p>Neutrophils are the most abundant immune cell, accounting for approximately 60% of circulating leukocytes [<xref ref-type="bibr" rid="B23-ijms-21-00836">23</xref>]. They contain primary (or azurophilic) granules, secondary granules and tertiary granules. Azurophilic granules contain hydrolases, myeloperoxidase (MPO) and neutrophil elastase, which can either target phagocytosed microbes in the phagolysosome or be uncontrollably released into the extracellular space at the site of infection [<xref ref-type="bibr" rid="B24-ijms-21-00836">24</xref>]. Secondary granules contain antimicrobial proteins such as lactoferrin and cathelicidin [<xref ref-type="bibr" rid="B24-ijms-21-00836">24</xref>]. Tertiary granules contain matrix metalloproteinase-9 (MMP-9), which is involved in the transmigration of neutrophils and in proteolytic degradation of the extracellular matrix [<xref ref-type="bibr" rid="B24-ijms-21-00836">24</xref>,<xref ref-type="bibr" rid="B25-ijms-21-00836">25</xref>]. Neutrophils release DNA structures that contain neutrophil-derived proteases [<xref ref-type="bibr" rid="B26-ijms-21-00836">26</xref>]. These structures, termed neutrophil extracellular traps (NETs), degrade virulence factors and kill bacteria [<xref ref-type="bibr" rid="B26-ijms-21-00836">26</xref>]. NETs account for a significant proportion of DNA found in mucus in the CF lung [<xref ref-type="bibr" rid="B26-ijms-21-00836">26</xref>]. Furthermore, there is evidence that CF neutrophils may inherently be defective [<xref ref-type="bibr" rid="B27-ijms-21-00836">27</xref>]. CF is characterised by recurrent and chronic bacterial infections and the CF lung is dominated by neutrophilic inflammation. Despite their protective role, the chronic presence of neutrophils in the CF lung can lead to irreversible damage to the lung parenchyma through their continued release of proteolytic enzymes [<xref ref-type="bibr" rid="B28-ijms-21-00836">28</xref>]. </p>
</sec>
</sec>
<sec id="sec3-ijms-21-00836">
<title>3. Proteases</title>
<p>There are five classes of proteases present in mammals: serine, cysteine, metallo, aspartic and threonine proteases, with the first four classes being the most prevalent in the human lung [<xref ref-type="bibr" rid="B29-ijms-21-00836">29</xref>]. Proteases were originally considered to have solely proteolytic properties. However, a growing body of research has uncovered their involvement in a series of intracellular and extracellular regulatory processes, including tissue remodelling, mucin expression, bacterial killing and neutrophil chemotaxis [<xref ref-type="bibr" rid="B29-ijms-21-00836">29</xref>]. With respect to the lung, proteases are secreted from bronchial epithelial cells and are also expressed in monocyte, lymphocyte and granulocyte cell lineages, especially in neutrophils [<xref ref-type="bibr" rid="B30-ijms-21-00836">30</xref>]. Proteases cleave extracellular matrix (ECM) proteins, antimicrobial peptides (AMPs) and antiproteases, and they have implications in the immune response to infection. In the healthy lung, proteases are involved in homeostasis and are contributory towards regeneration and repair processes [<xref ref-type="bibr" rid="B29-ijms-21-00836">29</xref>]. Elevated protease levels are associated with a large spectrum of pulmonary diseases, including idiopathic pulmonary fibrosis (IPF), emphysema, respiratory tract infections and CF [<xref ref-type="bibr" rid="B28-ijms-21-00836">28</xref>]. A number of proteases are expressed in the lung, such as cathepsin G (CatG) and MMPs [<xref ref-type="bibr" rid="B28-ijms-21-00836">28</xref>]. However, neutrophil elastase (NE) is a major protease released in the CF lung [<xref ref-type="bibr" rid="B31-ijms-21-00836">31</xref>], and its implications in CF will now be discussed further.</p>
<sec>
<title>Neutrophil Elastase</title>
<p>NE is a 29 kDa serine protease that is derived from the “elastase, neutrophil expressed” (<italic>ELANE)</italic> gene, found on chromosome 19 at position p13.3 [<xref ref-type="bibr" rid="B32-ijms-21-00836">32</xref>]. NE is stored in neutrophil azurophilic granules at a mean concentration of 5.33 mM [<xref ref-type="bibr" rid="B33-ijms-21-00836">33</xref>], and is released during neutrophil degranulation, NET formation or during neutrophil necrosis [<xref ref-type="bibr" rid="B31-ijms-21-00836">31</xref>]. Despite its name, NE not only degrades elastin, it also degrades most ECM proteins and some plasma proteins, such as collagen (types I-IV), laminin, fibronectin and proteoglycans [<xref ref-type="bibr" rid="B34-ijms-21-00836">34</xref>]. NE can also cleave coagulation factors, other proteases and antiproteases, leading to their activation or loss of function [<xref ref-type="bibr" rid="B28-ijms-21-00836">28</xref>,<xref ref-type="bibr" rid="B35-ijms-21-00836">35</xref>,<xref ref-type="bibr" rid="B36-ijms-21-00836">36</xref>].</p>
<p>Whilst NE’s proteolytic properties contribute to structural destruction of the airways, it is also involved in a number of other processes such as inflammation and the host response to infection (<xref ref-type="fig" rid="ijms-21-00836-f001">Figure 1</xref>). NE upregulates pro-inflammatory cytokine secretion, for example, it upregulates IL-8 secretion through indirect stimulation of TLR4 or TLR2 and their signalling cascades [<xref ref-type="bibr" rid="B37-ijms-21-00836">37</xref>,<xref ref-type="bibr" rid="B38-ijms-21-00836">38</xref>,<xref ref-type="bibr" rid="B39-ijms-21-00836">39</xref>]. This leads to further neutrophil recruitment, generating a continuous and destructive cycle of neutrophilic inflammation and protease release [<xref ref-type="bibr" rid="B40-ijms-21-00836">40</xref>]. Interestingly, this effect is reversed when NE activity is inhibited by the serine protease inhibitor, phenylmethylsulfonyl fluoride [<xref ref-type="bibr" rid="B40-ijms-21-00836">40</xref>]. Much like other proteases, NE can also impair the innate and adaptive immune system’s ability to clear infections. NE impairs mucociliary clearance by causing mucus hypersecretion via upregulating the expression of mucin genes such as <italic>MUC5AC</italic> and <italic>MUC5B</italic> [<xref ref-type="bibr" rid="B41-ijms-21-00836">41</xref>]. It was also shown to upregulate <italic>MUC4</italic> and <italic>MUC1</italic>, however, their roles in the lung are much less understood [<xref ref-type="bibr" rid="B42-ijms-21-00836">42</xref>,<xref ref-type="bibr" rid="B43-ijms-21-00836">43</xref>]. In addition to enhancing mucus secretion, NE also impairs ciliary function by degrading cilia and reducing their beat frequency [<xref ref-type="bibr" rid="B44-ijms-21-00836">44</xref>]. Altogether, the combination of mucus hypersecretion and ciliary dysfunction leads to mucus plugging and an increased predisposition to infection in CF individuals.</p>
<p>NE is necessary for pathogen clearance, however, it can also impair the innate immune system’s ability to resolve infections. It is essential for maximum clearance of intracellular Gram-negative bacteria by neutrophils [<xref ref-type="bibr" rid="B45-ijms-21-00836">45</xref>]. Additionally, NE, along with other serine proteases form NETs, which entrap and kill Gram-positive and Gram-negative bacteria [<xref ref-type="bibr" rid="B26-ijms-21-00836">26</xref>]. NE was shown to regulate NET formation, with NE knockout mice displaying the inability to form NETs in a <italic>Klebsiella pneumoniae</italic> infection model [<xref ref-type="bibr" rid="B46-ijms-21-00836">46</xref>].</p>
<p>In contrast to NE’s infection-resolving abilities, excess NE was shown to cleave and downregulate flagella, an important PAMP found on CF-associated pathogens, such as <italic>P. aeruginosa</italic> [<xref ref-type="bibr" rid="B47-ijms-21-00836">47</xref>,<xref ref-type="bibr" rid="B48-ijms-21-00836">48</xref>]. Flagella cleavage reduces the innate immune system’s ability to detect these pathogens via the TLR5 signalling pathway [<xref ref-type="bibr" rid="B47-ijms-21-00836">47</xref>]. NE can disrupt the complement signalling and clearance pathways by cleaving opsonising peptides, such as C3b and the cell surface receptor C5a [<xref ref-type="bibr" rid="B49-ijms-21-00836">49</xref>,<xref ref-type="bibr" rid="B50-ijms-21-00836">50</xref>]. It can also cleave macrophage apoptotic cell receptors such as CD36, impairing their ability to clear apoptotic cells [<xref ref-type="bibr" rid="B51-ijms-21-00836">51</xref>]. Lastly, NE was shown to cleave AMPs, such as β-defensins and lactoferrin [<xref ref-type="bibr" rid="B52-ijms-21-00836">52</xref>,<xref ref-type="bibr" rid="B53-ijms-21-00836">53</xref>]. In addition to its effects on the innate immune system, NE can also affect the adaptive immune system. Studies have shown that NE cleaves T-cell receptors, CD2, CD4, CD8 and CD14, impairing monocyte activation, antigen presentation and dendritic cell maturation [<xref ref-type="bibr" rid="B54-ijms-21-00836">54</xref>,<xref ref-type="bibr" rid="B55-ijms-21-00836">55</xref>]. Despite its original intention for resolving infections, excess NE secretion may in fact be detrimental for pathogen clearance, allowing for increased bacterial survival rates and the presence of recurrent and chronic infections in CF individuals.</p>
</sec>
</sec>
<sec id="sec4-ijms-21-00836">
<title>4. Antiproteases</title>
<p>In the healthy lung, proteases and antiproteases maintain a homeostatic balance, preventing any potential lung damage that may arise from proteases. CF lung disease is dominated by chronic and recurrent infections that are characterised predominantly by neutrophilic inflammation [<xref ref-type="bibr" rid="B56-ijms-21-00836">56</xref>]. In response to infection, neutrophils not only phagocytose microbes, they also release an abundance of proteases into the extracellular space, damaging surrounding structures if this process is uncontrolled or excessive [<xref ref-type="bibr" rid="B31-ijms-21-00836">31</xref>,<xref ref-type="bibr" rid="B56-ijms-21-00836">56</xref>,<xref ref-type="bibr" rid="B57-ijms-21-00836">57</xref>]. An imbalance in the protease/antiprotease balance is heavily implicated in CF pathophysiology [<xref ref-type="bibr" rid="B28-ijms-21-00836">28</xref>]. Several antiproteases are expressed in the lung [<xref ref-type="bibr" rid="B40-ijms-21-00836">40</xref>], and the three major serine antiproteases are elafin, secretory leukocyte protease inhibitor (SLPI) and alpha1-antitrypsin (A1AT).</p>
<p>The CF lung is a protease-rich environment and this protease burden overwhelms the antiprotease capabilities of its principle serine antiprotease, A1AT, leading to a protease-antiprotease imbalance, further damaging the CF lung. Despite the apparent deficit in A1AT function, CF individuals actually secrete increased levels of A1AT and other antiproteases [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. However, excessive serine protease activity, especially due to NE, leads to complex formation with and enzymatic cleavage of A1AT and other antiproteases such as SLPI and elafin, rendering them inactive [<xref ref-type="bibr" rid="B59-ijms-21-00836">59</xref>,<xref ref-type="bibr" rid="B60-ijms-21-00836">60</xref>,<xref ref-type="bibr" rid="B61-ijms-21-00836">61</xref>].</p>
<sec id="sec4dot1-ijms-21-00836">
<title>4.1. Elafin</title>
<p>The <italic>elafin</italic> gene codes for a 117 amino acid protein containing a signal peptide, enabling the secretion of a 95 amino acid precursor protein known as pre-elafin or trappin-2 [<xref ref-type="bibr" rid="B62-ijms-21-00836">62</xref>]. This precursor is cleaved by the enzyme tryptase to yield mature elafin—a small 6 kDa, 57 amino acid peptide [<xref ref-type="bibr" rid="B62-ijms-21-00836">62</xref>,<xref ref-type="bibr" rid="B63-ijms-21-00836">63</xref>]. Elafin is found constitutively expressed at many epithelial surfaces including the bronchial and alveolar cells of the lung, and in immune cells such as neutrophils and macrophages [<xref ref-type="bibr" rid="B64-ijms-21-00836">64</xref>,<xref ref-type="bibr" rid="B65-ijms-21-00836">65</xref>,<xref ref-type="bibr" rid="B66-ijms-21-00836">66</xref>,<xref ref-type="bibr" rid="B67-ijms-21-00836">67</xref>,<xref ref-type="bibr" rid="B68-ijms-21-00836">68</xref>]. Elafin is a potent inhibitor of NE and proteinase-3 (PR3) [<xref ref-type="bibr" rid="B69-ijms-21-00836">69</xref>,<xref ref-type="bibr" rid="B70-ijms-21-00836">70</xref>]. Elafin and trappin-2 exert antibacterial and antifungal effects independent of antiprotease activity [<xref ref-type="bibr" rid="B71-ijms-21-00836">71</xref>,<xref ref-type="bibr" rid="B72-ijms-21-00836">72</xref>]. Antiviral activity has also been reported [<xref ref-type="bibr" rid="B73-ijms-21-00836">73</xref>]. Additionally, elafin inhibits LPS-induced activation of the pro-inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) pathways [<xref ref-type="bibr" rid="B74-ijms-21-00836">74</xref>].</p>
</sec>
<sec id="sec4dot2-ijms-21-00836">
<title>4.2. SLPI</title>
<p>SLPI is an 11.7 kDa serine protease inhibitor that is comprised of 107 amino acid residues [<xref ref-type="bibr" rid="B75-ijms-21-00836">75</xref>,<xref ref-type="bibr" rid="B76-ijms-21-00836">76</xref>]. It inhibits a number of proteases, including NE, CatG, trypsin, chymotrypsin, chymase and tryptase [<xref ref-type="bibr" rid="B77-ijms-21-00836">77</xref>]. SLPI demonstrates a wide range of expression. It is expressed by a number of mucosal surfaces and is secreted by various cell types including neutrophils, macrophages and epithelial cells of the respiratory and gastro-intestinal tracts [<xref ref-type="bibr" rid="B29-ijms-21-00836">29</xref>]. Specifically in the lung, SLPI is secreted by the club cells and goblet cells of the respiratory epithelium; by the serous cells in submucosal glands; and by alveolar macrophages [<xref ref-type="bibr" rid="B78-ijms-21-00836">78</xref>]. SLPI’s antiprotease functions are particularly important in the upper airways [<xref ref-type="bibr" rid="B60-ijms-21-00836">60</xref>]. SLPI also has antimicrobial, anti-inflammatory and immunomodulatory activity [<xref ref-type="bibr" rid="B79-ijms-21-00836">79</xref>,<xref ref-type="bibr" rid="B80-ijms-21-00836">80</xref>,<xref ref-type="bibr" rid="B81-ijms-21-00836">81</xref>].</p>
</sec>
<sec id="sec4dot3-ijms-21-00836">
<title>4.3. A1AT</title>
<p>A1AT is an acute-phase 52 kDa glycoprotein that is primarily synthesised and secreted by liver hepatocytes and circulates systemically. Additionally, it is secreted in smaller quantities by neutrophils, monocytes and enterocytes, and by alveolar macrophages and bronchial epithelial cells in the lung [<xref ref-type="bibr" rid="B82-ijms-21-00836">82</xref>]. A1AT is present in all tissues around the body and it most notably inhibits NE, however it also inhibits a wide range of other proteases, including CatG, PR3, trypsin, chymotrypsin, plasmin, thrombin and factor Xa, amongst others [<xref ref-type="bibr" rid="B29-ijms-21-00836">29</xref>]. A1AT was also shown to improve bacterial clearance by preventing the cleavage of neutrophil surface complement receptors (e.g., CD35) and C-X-C Motif Chemokine Receptor 1 (CXCR1) receptors [<xref ref-type="bibr" rid="B83-ijms-21-00836">83</xref>]. The serum concentration of A1AT in a healthy individual is 85–250 mg/dL, showing a three- to five-fold increase during inflammation and injury [<xref ref-type="bibr" rid="B84-ijms-21-00836">84</xref>].</p>
</sec>
</sec>
<sec id="sec5-ijms-21-00836">
<title>5. Current Treatment of CF Lung Disease</title>
<p>The treatment of CF lung manifestations can be divided into various categories: (1) airway clearance therapies; (2) bronchodilators; (3) anti-inflammatory therapies; (4) infection prophylaxis and treatment; and (5) CFTR modulators; these have been extensively reviewed elsewhere [<xref ref-type="bibr" rid="B85-ijms-21-00836">85</xref>]. A number of experimental and established antiprotease therapies are also possible. CF patients with advanced pulmonary disease may also receive lung transplants and/or respiratory support [<xref ref-type="bibr" rid="B86-ijms-21-00836">86</xref>].</p>
</sec>
<sec id="sec6-ijms-21-00836">
<title>6. Novel Therapies for CF Lung Disease</title>
<sec id="sec6dot1-ijms-21-00836">
<title>6.1. Antiprotease Therapies</title>
<p>The CF lung is a protease-rich environment, and this protease burden overwhelms the protective abilities of endogenous antiproteases, placing the CF lung at greater risk for irreversible airway destruction. This protease/antiprotease imbalance largely contributes towards CF lung pathology [<xref ref-type="bibr" rid="B87-ijms-21-00836">87</xref>], prompting various research groups to investigate the therapeutic potential of antiproteases. Antiprotease therapies for CF can be divided into two distinct categories: antiprotease augmentation therapies and pharmacological protease inhibition [<xref ref-type="bibr" rid="B87-ijms-21-00836">87</xref>].</p>
<p>In the early 1990s, McElvaney et al. investigated the effects of A1AT augmentation therapy in CF patients through two different routes of administration: intravenously and aerosolized [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. Their initial study investigated the effects of intravenous administration of A1AT at doses ranging from 60 to 120 mg/kg in CF patients. They noticed that only the 120 mg/kg dose was sufficient to suppress the effects of NE. However, the effects were transient, with the re-emergence of active NE in bronchoalveolar lavage fluid (BALF) within one week of A1AT administration [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. The same group subsequently investigated the effects of administering higher doses of aerosolised A1AT to CF patients, ranging from 1.5 to 3 mg/kg A1AT twice daily for one week. Aerosolised administration of A1AT resulted in inhibition of NE and re-established anti-NE activity on the respiratory epithelium, but only if the A1AT level was above a certain threshold of 8 µM in BALF [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. The authors concluded that despite the therapeutic potential A1AT augmentation therapy offers, the marked variability of NE levels in the CF lung makes it difficult to determine an optimal dosage for A1AT administration [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. In contrast to the anti-NE effects observed in the previous studies, another study found that inhaled A1AT augmentation therapy did not substantially decrease anti-NE activity in CF induced sputum samples [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>]. However, these discrepancies may have possibly been due to the use of different aerosol devices across the two studies and also to the biological samples used to examine the antiprotease effects of inhaled A1AT therapy (BALF vs. induced sputum) [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>,<xref ref-type="bibr" rid="B88-ijms-21-00836">88</xref>].</p>
<p>Lately, much work has gone into developing novel protease inhibitors with the aim of improving their resistance against protease-mediated inactivation, in the hope of enhancing their antiprotease capabilities. This is achieved either through modifying pre-existing drugs/proteins, or by generating synthetic protease inhibitors. Initial studies investigated the use of recombinant forms of endogenous antiproteases, such as A1AT, SLPI and human monocyte/neutrophil elastase inhibitor (hMNEI) [<xref ref-type="bibr" rid="B89-ijms-21-00836">89</xref>,<xref ref-type="bibr" rid="B90-ijms-21-00836">90</xref>,<xref ref-type="bibr" rid="B91-ijms-21-00836">91</xref>,<xref ref-type="bibr" rid="B92-ijms-21-00836">92</xref>]. It was found that aerosolised administration of these recombinant antiproteases reduced the release of a variety of proteases, pro-inflammatory mediators, and in the case of recombinant hMNEI, enhanced bacterial clearance in murine models infected with <italic>P. aeruginosa</italic> [<xref ref-type="bibr" rid="B89-ijms-21-00836">89</xref>,<xref ref-type="bibr" rid="B90-ijms-21-00836">90</xref>,<xref ref-type="bibr" rid="B91-ijms-21-00836">91</xref>,<xref ref-type="bibr" rid="B92-ijms-21-00836">92</xref>]. Subsequent studies have also investigated the therapeutic potential of functional variants of the endogenous antiproteases, elafin and SLPI, and found that these variants retained their antiprotease properties, blunted the pro-inflammatory response to infection in the lung, and showcased an increased resistance to protease-mediated degradation [<xref ref-type="bibr" rid="B93-ijms-21-00836">93</xref>,<xref ref-type="bibr" rid="B94-ijms-21-00836">94</xref>].</p>
<p>A number of novel synthetic protease inhibitors have been identified for potential use in CF, with POL6014, DX-890, KRP-109, and AZD9668 being examples. POL6014 significantly reduces NE activity without impairing neutrophil function [<xref ref-type="bibr" rid="B95-ijms-21-00836">95</xref>] while DX-890 decreases pro-inflammatory cytokine secretion and neutrophil transmigration [<xref ref-type="bibr" rid="B96-ijms-21-00836">96</xref>]. KRP-109 may possibly reverse mucus plugging in the CF airways [<xref ref-type="bibr" rid="B97-ijms-21-00836">97</xref>]. However, a study by Yamada et al. investigating the effects of KRP-109 administration in murine pneumococcal models found that there was no difference in BALF NE activity between KRP-109-treated mice and controls [<xref ref-type="bibr" rid="B98-ijms-21-00836">98</xref>]. Nonetheless, they noticed that KRP-109 mice had higher survival rates, and histologic examination revealed reductions in alveolar inflammation [<xref ref-type="bibr" rid="B98-ijms-21-00836">98</xref>]. AZD9668 underwent phase 2a randomised-controlled, parallel-group clinical trials where patients either received oral AZD9668 or placebo for 4 weeks [<xref ref-type="bibr" rid="B99-ijms-21-00836">99</xref>]. AZD9688 was well-tolerated and led to reductions in free and total urinary desmosine—biomarkers of elastin degradation [<xref ref-type="bibr" rid="B99-ijms-21-00836">99</xref>]. However, there were no observable differences in sputum NE activity, lung function, respiratory symptoms, quality of life, or use of reliever medication between both treatment arms [<xref ref-type="bibr" rid="B99-ijms-21-00836">99</xref>]. Lastly, 2-O, 3-O-desulfated heparin (ODSH), doxycycline and N-Arylacyl O-sulfonated aminoglycosides were shown to exhibit antiprotease properties [<xref ref-type="bibr" rid="B100-ijms-21-00836">100</xref>,<xref ref-type="bibr" rid="B101-ijms-21-00836">101</xref>,<xref ref-type="bibr" rid="B102-ijms-21-00836">102</xref>,<xref ref-type="bibr" rid="B103-ijms-21-00836">103</xref>]. A summary of the findings from these various therapeutic antiprotease studies is outlined in <xref ref-type="table" rid="ijms-21-00836-t001">Table 1</xref>.</p>
</sec>
<sec id="sec6dot2-ijms-21-00836">
<title>6.2. A1AT Gene Therapy</title>
<p>An emerging area of research is A1AT gene therapy. Much of the published literature is directed towards A1AT deficiency (A1ATD); however, its findings may be applicable to CF given the similarities between the two diseases. Various studies investigated the effects of wild-type human <italic>A1AT</italic> gene (M-A1AT) transfer using retroviral and adenoviral vectors, and they showcased successful M-A1AT transfer, M-A1AT synthesis and secretion, although the effects were short-lived [<xref ref-type="bibr" rid="B105-ijms-21-00836">105</xref>]. It was also noted that both these vectors had associated side effects. Retroviral vectors were associated with hypotension, lethargy, hematemesis and death, which was observed in experiments using dog models [<xref ref-type="bibr" rid="B106-ijms-21-00836">106</xref>]. It is important to note that retroviral gene transfer was shown to be associated with an increased risk of mutagenesis, which causes neoplastic transformation [<xref ref-type="bibr" rid="B107-ijms-21-00836">107</xref>]. Adenoviral vectors, on the other hand, were shown to be highly immunogenic [<xref ref-type="bibr" rid="B108-ijms-21-00836">108</xref>]. As a way to combat the negative side effects of retroviral and adenoviral therapies, researchers investigated the use of recombinant adeno-associated viral vectors (rAAV) in M-A1AT therapy. rAAVs have become the gold-standard in gene therapy because of their low pathogenicity and immunogenicity [<xref ref-type="bibr" rid="B105-ijms-21-00836">105</xref>]. Unlike retroviruses, they do not integrate in their host cell’s genome, which removes the risk of insertional oncogenesis [<xref ref-type="bibr" rid="B105-ijms-21-00836">105</xref>]. rAAVs do exhibit immunogenic properties, such as the formation of neutralising antibodies, but they do not activate cytotoxic T-cells [<xref ref-type="bibr" rid="B105-ijms-21-00836">105</xref>]. Furthermore, rAAVs can also infect and persist in both dividing and non-dividing cells for long periods of time, allowing for prolonged gene expression [<xref ref-type="bibr" rid="B105-ijms-21-00836">105</xref>]. Since rAAVs have low pathogenicity and offer prolonged, gene expression, it has long been the focus of M-A1AT augmentation therapy research.</p>
<p>RNA interference (RNAi) is another potential approach to A1AT therapy. In contrast to A1AT augmentation therapy, RNAi is involved in the post-transcriptional silencing of proteins [<xref ref-type="bibr" rid="B109-ijms-21-00836">109</xref>]. One study investigated the effects of post-transcriptional silencing of mutated A1AT (Z-A1AT) by incorporating microRNAs into rAAVs [<xref ref-type="bibr" rid="B110-ijms-21-00836">110</xref>]. The effects on microRNA-mediated silencing of Z-A1AT came into question following the realisation that M-A1AT augmentation therapy failed to reduce Z-A1AT expression in tissues [<xref ref-type="bibr" rid="B110-ijms-21-00836">110</xref>]. Increased Z-A1AT expression results in the accumulation of mutant protein in hepatocytes, predisposing them to damage [<xref ref-type="bibr" rid="B110-ijms-21-00836">110</xref>]. It was found that dual microRNA and rAAV-based therapy resulted in long-term knockdown of circulating Z-A1AT [<xref ref-type="bibr" rid="B110-ijms-21-00836">110</xref>]. In addition, in vivo experiments showcased a significant and widespread decrease in Z-A1AT accumulation within hepatocytes [<xref ref-type="bibr" rid="B110-ijms-21-00836">110</xref>]. These findings suggest that dual microRNA and rAVV therapy has the potential to halt the progression of A1ATD-mediated liver disease. Although this study does not investigate the effects of microRNA-based gene therapies in the lung, it does serve to highlight its potential for the treatment of CF lung disease.</p>
</sec>
</sec>
<sec id="sec7-ijms-21-00836">
<title>7. microRNAs</title>
<p>microRNAs (miRNAs or miRs) are short non-coding RNAs that are around 20–25 nucleotides long [<xref ref-type="bibr" rid="B111-ijms-21-00836">111</xref>]. They are generated in a step-wise process and they negatively control gene expression through translational repression and/or degradation of its target messenger RNA (mRNA) [<xref ref-type="bibr" rid="B112-ijms-21-00836">112</xref>,<xref ref-type="bibr" rid="B113-ijms-21-00836">113</xref>]. This is accomplished through their sequence-specific hybridisation with miRNA responsive elements (MREs) in the 3’ untranslated region (3’UTR) of target mRNAs. miRNAs were first described in the early 1990s by Lee et al. in the nematode, <italic>Caenorhabditis elegans</italic> [<xref ref-type="bibr" rid="B114-ijms-21-00836">114</xref>], however the term “miRNA” was not coined until the early 2000s. Ever since their discovery, much research has gone into miRNAs and their roles in developmental biology and other biological processes, including proliferation and apoptosis [<xref ref-type="bibr" rid="B115-ijms-21-00836">115</xref>]. Aberrant miRNA expression was shown to be implicated in a number of physiological and pathological processes such as in ageing, cancer and autoimmune disease [<xref ref-type="bibr" rid="B116-ijms-21-00836">116</xref>,<xref ref-type="bibr" rid="B117-ijms-21-00836">117</xref>,<xref ref-type="bibr" rid="B118-ijms-21-00836">118</xref>]. In vitro modulation of miRNAs can be achieved using inhibition or augmentation strategies. Artificial overexpression of miRNAs can be achieved by transfection of miRNA mimics or genes expressing miRNAs into target cells [<xref ref-type="bibr" rid="B119-ijms-21-00836">119</xref>]. One commonly used method to inhibit miRNA experimentally is the use of locked nucleic acid cholesterol-tagged antisense oligonucleotides termed antagomirs [<xref ref-type="bibr" rid="B120-ijms-21-00836">120</xref>]. Recently, several research groups have explored the role of miRNAs in CF, and their findings will be outlined below.</p>
<sec id="sec7dot1-ijms-21-00836">
<title>7.1. miRNAs in CF</title>
<p>There are several miRNAs known to regulate CFTR expression, e.g., miR-145, miR-494, miR-223 and miR-509-3p [<xref ref-type="bibr" rid="B121-ijms-21-00836">121</xref>,<xref ref-type="bibr" rid="B122-ijms-21-00836">122</xref>,<xref ref-type="bibr" rid="B123-ijms-21-00836">123</xref>,<xref ref-type="bibr" rid="B124-ijms-21-00836">124</xref>]. Each of these has been found upregulated in primary bronchial brushings and/or airway epithelial cells from the CF lung [<xref ref-type="bibr" rid="B122-ijms-21-00836">122</xref>,<xref ref-type="bibr" rid="B123-ijms-21-00836">123</xref>]. miR-138 can also modulate CFTR expression through the influence of its mRNA target, the transcriptional regulator SIN3A [<xref ref-type="bibr" rid="B125-ijms-21-00836">125</xref>]. The calcium-activated chloride ion channel, ANO1, has also been shown to contribute to CF pathology and is downregulated in CF epithelium [<xref ref-type="bibr" rid="B126-ijms-21-00836">126</xref>]. ANO1 is targeted by miR-9, which is increased in fully differentiated bronchial epithelial cells from CF patients [<xref ref-type="bibr" rid="B127-ijms-21-00836">127</xref>].</p>
<p>Various studies have shown that miRNA dysregulation has implications in the innate immune response of CF individuals. For example, miR-126 is downregulated in CF bronchial brushings, and its target mRNA, target of Myb1 (TOM1; a negative regulator of the TLR2/4 pathway), is reciprocally upregulated [<xref ref-type="bibr" rid="B128-ijms-21-00836">128</xref>]. In contrast, another negative regulator of the TLR4 pro-inflammatory cascade, caveolin 1 (CAV1), is reduced in CF macrophages due to increased levels of miR-199a-5p [<xref ref-type="bibr" rid="B129-ijms-21-00836">129</xref>].</p>
<p>IL-8 is a major neutrophil chemokine that is present at elevated levels in the CF lung. miR-17 and miR-93 directly target IL-8 expression, and both miRs are decreased during <italic>P. aeruginosa</italic>-induced inflammation in CF bronchial epithelial cells [<xref ref-type="bibr" rid="B130-ijms-21-00836">130</xref>,<xref ref-type="bibr" rid="B131-ijms-21-00836">131</xref>]. Increased levels of miR-155 in CF further contribute to increased IL-8 by decreasing the target mRNA, Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1), as this enables stabilisation of the IL-8 mRNA transcript [<xref ref-type="bibr" rid="B132-ijms-21-00836">132</xref>]. In contrast, miR-146a is over-expressed in CF macrophages and is suggested to limit the inflammatory response through its targeting of IL-6 [<xref ref-type="bibr" rid="B133-ijms-21-00836">133</xref>].</p>
<p>In contrast to reduced miR-17 levels in CF bronchial brushings, miR-17 is upregulated in CF macrophages, where it targets key autophagy pathway molecules ATG7 and ATG16L1 [<xref ref-type="bibr" rid="B134-ijms-21-00836">134</xref>]. As well as dysfunctional autophagy, CF macrophages also display impaired phagocytosis. CF macrophages have increased miR-181b and thus lower levels of its target, a cell surface receptor recognised by lipoxin A4 [<xref ref-type="bibr" rid="B135-ijms-21-00836">135</xref>]. Inhibiting miR-181b restores lipoxin A4-induced phagocytic ability [<xref ref-type="bibr" rid="B135-ijms-21-00836">135</xref>].</p>
<p>As well as targeting SHIP1, miR-155 also controls the expression of regulatory-associated protein of mTOR, complex 1 (RPTOR) [<xref ref-type="bibr" rid="B136-ijms-21-00836">136</xref>]. This links the increased miR-155 levels in CF epithelial cells to the progressive fibrosis of the CF lung, as RPTOR inhibition activates the transforming growth factor beta (TGFβ) pathway to induce fibrosis [<xref ref-type="bibr" rid="B136-ijms-21-00836">136</xref>]. Ongoing destruction of healthy lung tissue in CF is also partly mediated by proteases. The elastolytic protease, cathepsin S, is increased in CF BALF and correlates with poorer lung function [<xref ref-type="bibr" rid="B137-ijms-21-00836">137</xref>]. miR-31, decreased in CF bronchial brushings, targets the transcription factor interferon regulatory factor 1 (IRF-1), thereby regulating cathepsin S expression [<xref ref-type="bibr" rid="B137-ijms-21-00836">137</xref>].</p>
<p>Finally, miRNAs also contribute to CF pathology via an effect on the unfolded protein response (UPR), a network of signalling pathways activated due to the endoplasmic reticulum (ER) stress arising from misfolded CFTR. miR-221 is increased in CF bronchial brushings, whilst its target, activating transcription factor 6 (ATF6; a transcription factor involved in the UPR), is decreased [<xref ref-type="bibr" rid="B138-ijms-21-00836">138</xref>]. The role of dysregulated miRNAs in CF and other lung diseases has been more extensively reviewed elsewhere, for example Glasgow et al. [<xref ref-type="bibr" rid="B139-ijms-21-00836">139</xref>] and Dutta et al. [<xref ref-type="bibr" rid="B140-ijms-21-00836">140</xref>].</p>
</sec>
<sec id="sec7dot2-ijms-21-00836">
<title>7.2. miRNA Therapeutics</title>
<p>Abnormally expressed mRNAs or proteins associated with disease represent therapeutic targets for miRNA-based drug development. Likewise, the same strategies can be employed if disease-associated miRNAs are to be targeted (<xref ref-type="table" rid="ijms-21-00836-t002">Table 2</xref>). </p>
<p>For example, in order to suppress the expression of an overly abundant disease-associated miRNA an inhibition approach may be adopted; conversely, to restore expression of a down-regulated miRNA, a miRNA mimic delivery strategy can be employed [<xref ref-type="bibr" rid="B141-ijms-21-00836">141</xref>]. In CF, where A1AT levels and activity are impaired for a variety of reasons, as discussed, an inhibition approach focusing on miRNAs that regulate the 3’UTR of the <italic>SERPINA1</italic> mRNA would appear to be worth considering. In theory, this should inhibit the target miRNA(s) and in turn increase expression of <italic>SERPINA1</italic> mRNA and protein. Two major approaches are possible—antagomirs or target site blockers (TSBs, also known as ‘masks’). Antagomirs are chemically modified synthetic antisense oligonucleotides which are complementary to a target miRNA. Once delivered inside a cell, an antagomir can bind to and sequester its target miRNA, thereby preventing it from negatively regulating all of its target mRNAs. As such, the effects of antagomirs can have substantial impact on pathways wherein the target miRNA affects different parts of the same biological process. However, this overall approach could have undesired off-target effects on other genes that are not part of the targeted pathway. A more precise method that may be required in other specific instances is the use of a TSB. In this approach, a locked-nucleic acid antisense oligonucleotide is custom-designed to compete specifically with a miRNA for binding to an individual miRNA recognition element within the 3’UTR of a target mRNA, hence preventing it from gaining access to those sites. </p>
<p>By their nature, nucleic acid-based therapies are prone to degradation by nucleases but also may activate the innate immune system. Therefore, delivery of miRNA-targeted therapeutics is a challenge. Many physiological barriers need to be overcome in order for the therapy to reach its site of action within a specific cell and to ensure it retains its activity whilst remaining invisible to the immune system. Optimising these processes is the focus of multiple cell biology, pharmaceutics and drug development projects. TargomiR is an intravenous miRNA mimic therapy for solid tumours in malignant pleural mesothelioma. The therapy is based on miR-16-loaded minicells and is a miRNA delivery therapy designed to restore the loss of miR-16 evident in malignant pleural mesothelioma patients. A Phase 1 open label dose-escalation study of TargomiR demonstrated tolerability and early signs of antitumour activity [<xref ref-type="bibr" rid="B142-ijms-21-00836">142</xref>]. miRNA inhibition therapies for lung disease have yet to progress to first-in-human studies. Recent and ongoing work in this group is focused on the identification of novel miRNAs that specifically regulate A1AT expression in monocytes or hepatocytes that could form the basis of miR-medicines targeting the protease/antiprotease imbalance in the CF lung, either locally or systemically [<xref ref-type="bibr" rid="B143-ijms-21-00836">143</xref>].</p>
</sec>
</sec>
<sec id="sec8-ijms-21-00836" sec-type="conclusions">
<title>8. Conclusions</title>
<p>As CF lung disease is so dominantly characterised by neutrophilic inflammation, the neutrophil serine protease NE is present at vastly excessive levels. In addition to causing damage by degrading its target extracellular matrix substrates, NE can aggravate lung inflammation. A1AT is the most abundant inhibitor of NE in the airways. However, the increased number of neutrophils in CF leads to a gross imbalance between NE activity and A1AT defences. Therapeutic enhancement of pulmonary A1AT could be a potential intervention to aid the control of NE-mediated destruction during CF exacerbations. As an alternative to the delivery of recombinant A1AT protein to the lung and its inherent caveats, a novel approach would be the delivery of molecules that drive A1AT expression in the patient’s own cells e.g., microRNA-targeted therapies.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Writing—original draft preparation, A.M.D.H., A.M.A.G., C.M.G.; writing—review and editing, A.M.D.H., A.M.A.G., H.H., C.M.G.; funding acquisition, C.M.G., A.M.A.G. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>Funding for research in this group is gratefully acknowledged from the Vertex Pharmaceuticals VIA program 2018 to C.M.G. and A.M.A.G., Horizon 2020 (MSCA-IF award 707771 GENDER-CF) to A.M.A.G., and an Alpha-1 Foundation Postdoctoral Fellowship 2019 to A.M.A.G. The APC was funded by Vertex Pharmaceuticals.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors have no relevant conflicts of interest to disclose other than the receipt of funding from the agencies named above. Vertex Pharmaceuticals read and agreed to the published version of the manuscript.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">3’UTR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">3’ Untranslated region</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">A1AT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Alpha-1 antitrypsin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">A1ATD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Alpha-1 antitrypsin deficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ABC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Adenosine triphosphate binding cassette</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Antimicrobial peptide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ANO1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Anoctamin 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AP-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Activator protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ATF6</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Activating transcription factor 6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ATP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Adenosine triphosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BALF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Bronchoalveolar lavage fluid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CatG</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cathepsin G</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CAV1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Caveolin 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cystic fibrosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CFTR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cystic fibrosis transmembrane conductance regulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CXCR1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">C-X-C Motif Chemokine Receptor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ECM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Extracellular matrix </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ELANE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Elastase, neutrophil expressed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ELF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Epithelial lining fluid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ER</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Endoplasmic reticulum</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">hMNEI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Human monocyte/neutrophil elastase inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IPF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IRF-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Interferon regulatory factor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MCP-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Monocyte chemoattractant protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">miRNA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Micro RNA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MMP-9</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Matrix metalloproteinase 9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MPO</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Myeloperoxidase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MRE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Micro RNA responsive element</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Messenger RNA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Neutrophil elastase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NET</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Neutrophil extracellular trap</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NF-κB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nuclear factor kappa-light-chain-enhancer of activated B cells;</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ODSH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">2-<italic>O</italic>, 3-<italic>O</italic>-desulfated heparin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PAMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pathogen associated molecular pattern</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PR3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Proteinase 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PRR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pattern recognition receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">rAAV</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Recombinant adeno-associated viral vector</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RNAi</td>
<td align="left" colspan="1" rowspan="1" valign="middle">RNA interference</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RPTOR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Regulatory-associated protein of mTOR, complex 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SHIP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Src homology-2 domain-containing inositol 5-phosphatase 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SLPI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Secretory leukocyte protease inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TSB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Target site blocker</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TGFβ</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Transforming growth factor beta</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TIMP-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Tissue inhibitor of metalloproteinase 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TLR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Toll-like receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TOM1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Target of Myb1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TSB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Target site blockers</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">UPR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Unfolded protein response</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-21-00836">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tobin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, 1286 and treatment</article-title>
<source/>Off. J. Am. Acad. Physician Assist.
          <year>2017</year>
<volume>30</volume>
<fpage>23</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1097/01.JAA.0000515540.36581.92</pub-id>
<pub-id pub-id-type="pmid">28441669</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-21-00836">
<label>2.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Noyes</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Lechner</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Presentation and management of cystic fibrosis</article-title>
<source/>Respiratory: An Integrated Approach to Disease
          <person-group person-group-type="editor">
<name>
<surname>Lechner</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Matuschak</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Brink</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<publisher-name>McGraw-Hill Education</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2015</year>
</element-citation>
</ref>
<ref id="B3-ijms-21-00836">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zielenski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rozmahel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bozon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kerem</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grzelczak</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Riordan</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Rommens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tsui</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (cftr) gene</article-title>
<source/>Genomics
          <year>1991</year>
<volume>10</volume>
<fpage>214</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1016/0888-7543(91)90503-7</pub-id>
<pub-id pub-id-type="pmid">1710598</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-21-00836">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Annilo</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Evolution of the atp-binding cassette (abc) transporter superfamily in vertebrates</article-title>
<source/>Annu. Rev. Genom. Hum. Genet.
          <year>2005</year>
<volume>6</volume>
<fpage>123</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.genom.6.080604.162122</pub-id>
<pub-id pub-id-type="pmid">16124856</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-21-00836">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname>
<given-names>C.F.</given-names>
</name>
</person-group>
<article-title>Abc transporters: From microorganisms to man</article-title>
<source/>Annu. Rev. Cell Biol.
          <year>1992</year>
<volume>8</volume>
<fpage>67</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.cb.08.110192.000435</pub-id>
<pub-id pub-id-type="pmid">1282354</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-21-00836">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berdiev</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Qadri</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Benos</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Assessment of the cftr and enac association</article-title>
<source/>Mol. Biosyst.
          <year>2009</year>
<volume>5</volume>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1039/B810471A</pub-id>
<pub-id pub-id-type="pmid">19156256</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-21-00836">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ousingsawat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wanitchakool</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kunzelmann</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Epithelial chloride transport by cftr requires tmem16a</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>12397</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-10910-0</pub-id>
<pub-id pub-id-type="pmid">28963502</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-21-00836">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haq</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Garnett</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brodlie</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Airway surface liquid homeostasis in cystic fibrosis: Pathophysiology and therapeutic targets</article-title>
<source/>Thorax
          <year>2016</year>
<volume>71</volume>
<fpage>284</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207588</pub-id>
<pub-id pub-id-type="pmid">26719229</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-21-00836">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derichs</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis</article-title>
<source/>Eur. Respir. Rev.
          <year>2013</year>
<volume>22</volume>
<fpage>58</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1183/09059180.00008412</pub-id>
<pub-id pub-id-type="pmid">23457166</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-21-00836">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Boeck</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Progress in therapies for cystic fibrosis</article-title>
<source/>Lancet Respir. Med.
          <year>2016</year>
<volume>4</volume>
<fpage>662</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(16)00023-0</pub-id>
<pub-id pub-id-type="pmid">27053340</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-21-00836">
<label>11.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Katkin</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Cystic Fibrosis: Clinical Manifestations of Pulmonary Disease. UpToDate: 2019</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/cystic-fibrosis-clinical-manifestations-of-pulmonary-disease">https://www.uptodate.com/contents/cystic-fibrosis-clinical-manifestations-of-pulmonary-disease</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-07-25">(accessed on 25 July 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B12-ijms-21-00836">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Ramsey</surname>
<given-names>B.W.</given-names>
</name>
</person-group>
<article-title>Pathophysiology and management of pulmonary infections in cystic fibrosis</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2003</year>
<volume>168</volume>
<fpage>918</fpage>
<lpage>951</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.200304-505SO</pub-id>
<pub-id pub-id-type="pmid">14555458</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-21-00836">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surette</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>The cystic fibrosis lung microbiome</article-title>
<source/>Ann. Am. Thorac. Soc.
          <year>2014</year>
<volume>11</volume>
<fpage>S61</fpage>
<lpage>S65</lpage>
<pub-id pub-id-type="doi">10.1513/AnnalsATS.201306-159MG</pub-id>
<pub-id pub-id-type="pmid">24437409</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-21-00836">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaplin</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Overview of the immune response</article-title>
<source/>J. Allergy Clin. Immunol.
          <year>2010</year>
<volume>125</volume>
<fpage>S3</fpage>
<lpage>S23</lpage>
<pub-id pub-id-type="pmid">20176265</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-21-00836">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Deriy</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>F.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Naren</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Bindokas</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cftr regulates phagosome acidification in macrophages and alters bactericidal activity</article-title>
<source/>Nat. Cell Biol.
          <year>2006</year>
<volume>8</volume>
<fpage>933</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.1038/ncb1456</pub-id>
<pub-id pub-id-type="pmid">16921366</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-21-00836">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruscia</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.X.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Caputo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shenoy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Abnormal trafficking and degradation of tlr4 underlie the elevated inflammatory response in cystic fibrosis</article-title>
<source/>J. Immunol.
          <year>2011</year>
<volume>186</volume>
<fpage>6990</fpage>
<lpage>6998</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1100396</pub-id>
<pub-id pub-id-type="pmid">21593379</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-21-00836">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopp</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Abdulrahman</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Khweek</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Akhter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Montione</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tazi</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Caution</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McCoy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Amer</surname>
<given-names>A.O.</given-names>
</name>
</person-group>
<article-title>Exaggerated inflammatory responses mediated by burkholderia cenocepacia in human macrophages derived from cystic fibrosis patients</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2012</year>
<volume>424</volume>
<fpage>221</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2012.06.066</pub-id>
<pub-id pub-id-type="pmid">22728038</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-21-00836">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruscia</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Bonfield</surname>
<given-names>T.L.</given-names>
</name>
</person-group>
<article-title>Cystic fibrosis lung immunity: The role of the macrophage</article-title>
<source/>J. Innate Immun.
          <year>2016</year>
<volume>8</volume>
<fpage>550</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1159/000446825</pub-id>
<pub-id pub-id-type="pmid">27336915</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-21-00836">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaman</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Gelrud</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Junaidi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Warny</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shea</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaf508 cystic fibrosis transmembrane conductance regulator gene mutation is altered</article-title>
<source/>Clin. Diagn. Lab. Immunol.
          <year>2004</year>
<volume>11</volume>
<fpage>819</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="pmid">15358638</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-21-00836">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Montresor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bolomini-Vittori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caldrer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dusi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Angiari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Vezzalini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leal</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations of cystic fibrosis transmembrane conductance regulator gene cause a monocyte-selective adhesion deficiency</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2016</year>
<volume>193</volume>
<fpage>1123</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201510-1922OC</pub-id>
<pub-id pub-id-type="pmid">26694899</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-21-00836">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Porto</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cifani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Guarnieri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Di Domenico</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Mariggio</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Spadaro</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guglietta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anile</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Venuta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Quattrucci</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysfunctional cftr alters the bactericidal activity of human macrophages against pseudomonas aeruginosa</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e19970</elocation-id>
<pub-id pub-id-type="pmid">21625641</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-21-00836">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham</surname>
<given-names>C.T.</given-names>
</name>
</person-group>
<article-title>Neutrophil serine proteases fine-tune the inflammatory response</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2008</year>
<volume>40</volume>
<fpage>1317</fpage>
<lpage>1333</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2007.11.008</pub-id>
<pub-id pub-id-type="pmid">18180196</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-21-00836">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathur</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Kuse</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Scalable system for classification of white blood cells from leishman stained blood stain images</article-title>
<source/>J. Pathol. Inform.
          <year>2013</year>
<volume>4</volume>
<fpage>S15</fpage>
<pub-id pub-id-type="doi">10.4103/2153-3539.109883</pub-id>
<pub-id pub-id-type="pmid">23766937</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-21-00836">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faurschou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borregaard</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Neutrophil granules and secretory vesicles in inflammation</article-title>
<source/>Microbes Infect.
          <year>2003</year>
<volume>5</volume>
<fpage>1317</fpage>
<lpage>1327</lpage>
<pub-id pub-id-type="doi">10.1016/j.micinf.2003.09.008</pub-id>
<pub-id pub-id-type="pmid">14613775</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-21-00836">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keck</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Balcom</surname>
<given-names>J.H.t.</given-names>
</name>
<name>
<surname>Fernandez-del Castillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Antoniu</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Warshaw</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat</article-title>
<source/>Gastroenterology
          <year>2002</year>
<volume>122</volume>
<fpage>188</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1053/gast.2002.30348</pub-id>
<pub-id pub-id-type="pmid">11781293</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-21-00836">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinkmann</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Reichard</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Goosmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fauler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Uhlemann</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Weinrauch</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zychlinsky</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neutrophil extracellular traps kill bacteria</article-title>
<source/>Science
          <year>2004</year>
<volume>303</volume>
<fpage>1532</fpage>
<lpage>1535</lpage>
<pub-id pub-id-type="doi">10.1126/science.1092385</pub-id>
<pub-id pub-id-type="pmid">15001782</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-21-00836">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gifford</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Chalmers</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>The role of neutrophils in cystic fibrosis</article-title>
<source/>Curr. Opin. Hematol.
          <year>2014</year>
<volume>21</volume>
<fpage>16</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1097/MOH.0000000000000009</pub-id>
<pub-id pub-id-type="pmid">24253427</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-21-00836">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taggart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Lalmanach</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cataldo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Janciauskiene</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Meiners</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Overall</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protean proteases: At the cutting edge of lung diseases</article-title>
<source/>Eur. Respir. J.
          <year>2017</year>
<volume>49</volume>
<fpage>1501200</fpage>
<pub-id pub-id-type="doi">10.1183/13993003.01200-2015</pub-id>
<pub-id pub-id-type="pmid">28179435</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-21-00836">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Proteases and antiproteases in chronic neutrophilic lung disease – relevance to drug discovery</article-title>
<source/>Br. J. Pharmacol.
          <year>2009</year>
<volume>158</volume>
<fpage>1048</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00448.x</pub-id>
<pub-id pub-id-type="pmid">19845686</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-21-00836">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jaspers</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants</article-title>
<source/>Am. J. Physiol. Lung Cell. Mol. Physiol.
          <year>2015</year>
<volume>308</volume>
<fpage>L1189</fpage>
<lpage>L1201</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00028.2015</pub-id>
<pub-id pub-id-type="pmid">25888573</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-21-00836">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Twigg</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Brockbank</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>FitzGerald</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The role of serine proteases and antiproteases in the cystic fibrosis lung</article-title>
<source/>Mediat. Inflamm.
          <year>2015</year>
<volume>2015</volume>
<fpage>293053</fpage>
<pub-id pub-id-type="doi">10.1155/2015/293053</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-21-00836">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Medcalf</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Mattmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lichter</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1992</year>
<volume>89</volume>
<fpage>8215</fpage>
<lpage>8219</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.89.17.8215</pub-id>
<pub-id pub-id-type="pmid">1518849</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-21-00836">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liou</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Nonisotropic enzyme--inhibitor interactions: A novel nonoxidative mechanism for quantum proteolysis by human neutrophils</article-title>
<source/>Biochemistry
          <year>1995</year>
<volume>34</volume>
<fpage>16171</fpage>
<lpage>16177</lpage>
<pub-id pub-id-type="doi">10.1021/bi00049a032</pub-id>
<pub-id pub-id-type="pmid">8519774</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-21-00836">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Katsuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Human neutrophil elastase: Degradation of basement membrane components and immunolocalization in the tissue</article-title>
<source/>J. Biochem.
          <year>1990</year>
<volume>108</volume>
<fpage>753</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a123277</pub-id>
<pub-id pub-id-type="pmid">1982000</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-21-00836">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borensztajn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Peppelenbosch</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Spek</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Factor xa: At the crossroads between coagulation and signaling in physiology and disease</article-title>
<source/>Trends Mol. Med.
          <year>2008</year>
<volume>14</volume>
<fpage>429</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2008.08.001</pub-id>
<pub-id pub-id-type="pmid">18774340</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-21-00836">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercer</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Chambers</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Coagulation and coagulation signalling in fibrosis</article-title>
<source/>Biochim. Biophys. Acta (BBA)–Mol. Basis Dis.
          <year>2013</year>
<volume>1832</volume>
<fpage>1018</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2012.12.013</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-21-00836">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devaney</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4</article-title>
<source/>FEBS Lett.
          <year>2003</year>
<volume>544</volume>
<fpage>129</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(03)00482-4</pub-id>
<pub-id pub-id-type="pmid">12782302</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-21-00836">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Interleukin-8 up-regulation by neutrophil elastase is mediated by myd88/irak/traf-6 in human bronchial epithelium</article-title>
<source/>J. Biol. Chem.
          <year>2001</year>
<volume>276</volume>
<fpage>35494</fpage>
<lpage>35499</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M103543200</pub-id>
<pub-id pub-id-type="pmid">11461907</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-21-00836">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurt-Jones</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Mandell</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Whitney</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Padgett</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gosselin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Newburger</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Finberg</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Role of toll-like receptor 2 (tlr2) in neutrophil activation: Gm-csf enhances tlr2 expression and tlr2-mediated interleukin 8 responses in neutrophils</article-title>
<source/>Blood
          <year>2002</year>
<volume>100</volume>
<fpage>1860</fpage>
<lpage>1868</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V100.5.1860.h81702001860_1860_1868</pub-id>
<pub-id pub-id-type="pmid">12176910</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-21-00836">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Targeting neutrophil elastase in cystic fibrosis</article-title>
<source/>Expert Opin. Ther. Targets
          <year>2008</year>
<volume>12</volume>
<fpage>145</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1517/14728222.12.2.145</pub-id>
<pub-id pub-id-type="pmid">18208364</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-21-00836">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgel</surname>
<given-names>P.-R.</given-names>
</name>
<name>
<surname>Montani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Danel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dusser</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Nadel</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>A morphometric study of mucins and small airway plugging in cystic fibrosis</article-title>
<source/>Thorax
          <year>2007</year>
<volume>62</volume>
<fpage>153</fpage>
<pub-id pub-id-type="doi">10.1136/thx.2006.062190</pub-id>
<pub-id pub-id-type="pmid">16928707</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-21-00836">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Cuellar</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>de Freytas</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carraway</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Voynow</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase increases muc4 expression in normal human bronchial epithelial cells</article-title>
<source/>Am. J. Physiol. Lung Cell. Mol. Physiol.
          <year>2003</year>
<volume>284</volume>
<fpage>L671</fpage>
<lpage>L679</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00220.2002</pub-id>
<pub-id pub-id-type="pmid">12495942</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-21-00836">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuwahara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lillehoj</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Hisatsune</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Isohama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.C.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase stimulates muc1 gene expression through increased sp1 binding to the muc1 promoter</article-title>
<source/>Am. J. Physiol. Lung Cell. Mol. Physiol.
          <year>2005</year>
<volume>289</volume>
<fpage>L355</fpage>
<lpage>L362</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00040.2005</pub-id>
<pub-id pub-id-type="pmid">15849214</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-21-00836">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chalmers</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Suarez-Cuartin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sibila</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Finch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Furrie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dicker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wrobel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2017</year>
<volume>195</volume>
<fpage>1384</fpage>
<lpage>1393</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201605-1027OC</pub-id>
<pub-id pub-id-type="pmid">27911604</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-21-00836">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belaaouaj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis</article-title>
<source/>Nat. Med.
          <year>1998</year>
<volume>4</volume>
<fpage>615</fpage>
<lpage>618</lpage>
<pub-id pub-id-type="doi">10.1038/nm0598-615</pub-id>
<pub-id pub-id-type="pmid">9585238</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-21-00836">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papayannopoulos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Metzler</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Hakkim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zychlinsky</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps</article-title>
<source/>J. Cell Biol.
          <year>2010</year>
<volume>191</volume>
<fpage>677</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201006052</pub-id>
<pub-id pub-id-type="pmid">20974816</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-21-00836">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Boado</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Espinola</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bahr</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Belaaouaj</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity</article-title>
<source/>J. Immunol. (Baltimore, Md.: 1950)
          <year>2004</year>
<volume>172</volume>
<fpage>509</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.172.1.509</pub-id>
<pub-id pub-id-type="pmid">14688361</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-21-00836">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonawane</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jyot</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>During</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ramphal</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in pseudomonas aeruginosa</article-title>
<source/>Infect. Immun.
          <year>2006</year>
<volume>74</volume>
<fpage>6682</fpage>
<lpage>6689</lpage>
<pub-id pub-id-type="doi">10.1128/IAI.00922-06</pub-id>
<pub-id pub-id-type="pmid">16982831</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-21-00836">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tosi</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Zakem</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase cleaves c3bi on opsonized pseudomonas as well as cr1 on neutrophils to create a functionally important opsonin receptor mismatch</article-title>
<source/>J. Clin. Investig.
          <year>1990</year>
<volume>86</volume>
<fpage>300</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1172/JCI114699</pub-id>
<pub-id pub-id-type="pmid">2164045</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-21-00836">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Berg</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Tambourgi</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Hoong</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Spiller</surname>
<given-names>O.B.</given-names>
</name>
<name>
<surname>McGreal</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Mechanism of neutrophil dysfunction: Neutrophil serine proteases cleave and inactivate the c5a receptor</article-title>
<source/>J. Immunol.
          <year>2014</year>
<volume>192</volume>
<fpage>1787</fpage>
<lpage>1795</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1301920</pub-id>
<pub-id pub-id-type="pmid">24446515</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-21-00836">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vandivier</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Fadok</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Bratton</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Penvari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Brain</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Accurso</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Henson</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis</article-title>
<source/>J. Clin. Investig.
          <year>2002</year>
<volume>109</volume>
<fpage>661</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1172/JCI0213572</pub-id>
<pub-id pub-id-type="pmid">11877474</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-21-00836">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogan</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis</article-title>
<source/>J. Infect. Dis.
          <year>2004</year>
<volume>190</volume>
<fpage>1245</fpage>
<lpage>1253</lpage>
<pub-id pub-id-type="doi">10.1086/423821</pub-id>
<pub-id pub-id-type="pmid">15346334</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-21-00836">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Neutrophil elastase up-regulates human beta-defensin-2 expression in human bronchial epithelial cells</article-title>
<source/>FEBS Lett.
          <year>2003</year>
<volume>546</volume>
<fpage>233</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(03)00577-5</pub-id>
<pub-id pub-id-type="pmid">12832046</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-21-00836">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doring</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Boudier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fleischer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bellon</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Cleavage of lymphocyte surface antigens cd2, cd4, and cd8 by polymorphonuclear leukocyte elastase and cathepsin g in patients with cystic fibrosis</article-title>
<source/>J. Immunol.
          <year>1995</year>
<volume>154</volume>
<fpage>4842</fpage>
<lpage>4850</lpage>
<pub-id pub-id-type="pmid">7722333</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-21-00836">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le-Barillec</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Si-Tahar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Balloy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Chignard</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Proteolysis of monocyte cd14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation</article-title>
<source/>J. Clin. Investig.
          <year>1999</year>
<volume>103</volume>
<fpage>1039</fpage>
<lpage>1046</lpage>
<pub-id pub-id-type="doi">10.1172/JCI5779</pub-id>
<pub-id pub-id-type="pmid">10194477</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-21-00836">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nichols</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Chmiel</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Inflammation and its genesis in cystic fibrosis</article-title>
<source/>Pediatric Pulmonol.
          <year>2015</year>
<volume>40</volume>
<fpage>S39</fpage>
<lpage>S56</lpage>
<pub-id pub-id-type="doi">10.1002/ppul.23242</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-21-00836">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantin</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Hartl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Konstan</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Chmiel</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy</article-title>
<source/>J. Cyst. Fibros: Off. J. Eur. Cyst. Fibros. Soc.
          <year>2015</year>
<volume>14</volume>
<fpage>419</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcf.2015.03.003</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-21-00836">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Alpha-1 antitrypsin therapy in cystic fibrosis and the lung disease associated with alpha-1 antitrypsin deficiency</article-title>
<source/>Ann. Am. Thorac. Soc.
          <year>2016</year>
<volume>13</volume>
<fpage>S191</fpage>
<lpage>S196</lpage>
<pub-id pub-id-type="pmid">27115956</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-21-00836">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chevallier</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Proteolytic inactivation of alpha 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis</article-title>
<source/>Eur. Respir. J.
          <year>1991</year>
<volume>4</volume>
<fpage>40</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">2026237</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-21-00836">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>McAuley</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Wartelle</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Belaaouaj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation</article-title>
<source/>J. Immunol.
          <year>2009</year>
<volume>183</volume>
<fpage>8148</fpage>
<lpage>8156</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0901716</pub-id>
<pub-id pub-id-type="pmid">20007580</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-21-00836">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyot</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis</article-title>
<source/>J. Biol. Chem.
          <year>2008</year>
<volume>283</volume>
<fpage>32377</fpage>
<lpage>32385</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M803707200</pub-id>
<pub-id pub-id-type="pmid">18799464</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-21-00836">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallenave</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>1993</year>
<volume>8</volume>
<fpage>439</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1165/ajrcmb/8.4.439</pub-id>
<pub-id pub-id-type="pmid">8476637</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-21-00836">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiedow</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Christophers</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Elafin: An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence</article-title>
<source/>J. Biol. Chem.
          <year>1990</year>
<volume>265</volume>
<fpage>14791</fpage>
<lpage>14795</lpage>
<pub-id pub-id-type="pmid">2394696</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-21-00836">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vos</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>van Sterkenburg</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Rabe</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Schalkwijk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hiemstra</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Datson</surname>
<given-names>N.A.</given-names>
</name>
</person-group>
<article-title>Transcriptional response of bronchial epithelial cells to pseudomonas aeruginosa: Identification of early mediators of host defense</article-title>
<source/>Physiol. Genom.
          <year>2005</year>
<volume>21</volume>
<fpage>324</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1152/physiolgenomics.00289.2004</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-21-00836">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallenave</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Shulmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crossley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jordana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gauldie</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Regulation of secretory leukocyte proteinase inhibitor (slpi) and elastase-specific inhibitor (esi/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>1994</year>
<volume>11</volume>
<fpage>733</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1165/ajrcmb.11.6.7946401</pub-id>
<pub-id pub-id-type="pmid">7946401</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-21-00836">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Haslett</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sallenave</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type ii alveolar epithelial cells</article-title>
<source/>FEBS Lett.
          <year>1999</year>
<volume>457</volume>
<fpage>33</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(99)01004-2</pub-id>
<pub-id pub-id-type="pmid">10486558</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-21-00836">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallenave</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Si Tahar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chignard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gauldie</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils</article-title>
<source/>J. Leukoc. Biol.
          <year>1997</year>
<volume>61</volume>
<fpage>695</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1002/jlb.61.6.695</pub-id>
<pub-id pub-id-type="pmid">9201260</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-21-00836">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mihaila</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor</article-title>
<source/>Zeitschrift fur Naturforschung. C J. Biosci.
          <year>2001</year>
<volume>56</volume>
<fpage>291</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1515/znc-2001-3-420</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-21-00836">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>Q.L.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin</article-title>
<source/>Biochemistry
          <year>1993</year>
<volume>32</volume>
<fpage>1866</fpage>
<lpage>1874</lpage>
<pub-id pub-id-type="doi">10.1021/bi00058a021</pub-id>
<pub-id pub-id-type="pmid">8439544</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-21-00836">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>Q.L.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Kinetics of the inhibition of proteinase 3 by elafin</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>2001</year>
<volume>24</volume>
<fpage>83</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1165/ajrcmb.24.1.4300</pub-id>
<pub-id pub-id-type="pmid">11152654</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-21-00836">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Govan</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Haslett</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sallenave</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens</article-title>
<source/>FEBS Lett.
          <year>1999</year>
<volume>452</volume>
<fpage>309</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(99)00670-5</pub-id>
<pub-id pub-id-type="pmid">10386612</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-21-00836">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zani</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Chandenier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dallet-Choisy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function</article-title>
<source/>FEBS J.
          <year>2008</year>
<volume>275</volume>
<fpage>2008</fpage>
<lpage>2020</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06355.x</pub-id>
<pub-id pub-id-type="pmid">18341586</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-21-00836">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Cu-Uvin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wira</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Trappin-2/elafin: A novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract</article-title>
<source/>Immunology
          <year>2010</year>
<volume>129</volume>
<fpage>207</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2567.2009.03165.x</pub-id>
<pub-id pub-id-type="pmid">19824918</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-21-00836">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Elafin prevents lipopolysaccharide-induced ap-1 and nf-kappab activation via an effect on the ubiquitin-proteasome pathway</article-title>
<source/>J. Biol. Chem.
          <year>2006</year>
<volume>281</volume>
<fpage>34730</fpage>
<lpage>34735</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M604844200</pub-id>
<pub-id pub-id-type="pmid">16980310</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-21-00836">
<label>75.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Crystal</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<source/>The Lung
          <publisher-name>Lipincott-Raven</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>1997</year>
</element-citation>
</ref>
<ref id="B76-ijms-21-00836">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seemuller</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Arnhold</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wiedenmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Machleidt</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Heinzel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Appelhans</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gassen</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Lottspeich</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The acid-stable proteinase inhibitor of human mucous secretions (husi-i, antileukoprotease). Complete amino acid sequence as revealed by protein and cdna sequencing and structural homology to whey proteins and red sea turtle proteinase inhibitor</article-title>
<source/>FEBS Lett.
          <year>1986</year>
<volume>199</volume>
<fpage>43</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(86)81220-0</pub-id>
<pub-id pub-id-type="pmid">3485543</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-21-00836">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doumas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kolokotronis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stefanopoulos</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor</article-title>
<source/>Infect. Immun.
          <year>2005</year>
<volume>73</volume>
<fpage>1271</fpage>
<lpage>1274</lpage>
<pub-id pub-id-type="doi">10.1128/IAI.73.3.1271-1274.2005</pub-id>
<pub-id pub-id-type="pmid">15731023</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-21-00836">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiemstra</surname>
<given-names>P.S.</given-names>
</name>
</person-group>
<article-title>Novel roles of protease inhibitors in infection and inflammation</article-title>
<source/>Biochem. Soc. Trans.
          <year>2002</year>
<volume>30</volume>
<fpage>116</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1042/bst0300116</pub-id>
<pub-id pub-id-type="pmid">12023837</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-21-00836">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>S.-A.</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Secretory leucoprotease inhibitor binds to nf-kappab binding sites in monocytes and inhibits p65 binding</article-title>
<source/>J. Exp. Med.
          <year>2005</year>
<volume>202</volume>
<fpage>1659</fpage>
<lpage>1668</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20050768</pub-id>
<pub-id pub-id-type="pmid">16352738</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-21-00836">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lentsch</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Czermak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Younkin</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Sarma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Inhibition of nf-kappab activation and augmentation of ikappabbeta by secretory leukocyte protease inhibitor during lung inflammation</article-title>
<source/>Am. J. Pathol.
          <year>1999</year>
<volume>154</volume>
<fpage>239</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)65270-4</pub-id>
<pub-id pub-id-type="pmid">9916938</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-21-00836">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced ikappabalpha degradation without affecting phosphorylation or ubiquitination</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>33648</fpage>
<lpage>33653</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M203710200</pub-id>
<pub-id pub-id-type="pmid">12084717</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-21-00836">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Nolan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
</person-group>
<article-title>Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency</article-title>
<source/>J. Immunol.
          <year>2010</year>
<volume>184</volume>
<fpage>4538</fpage>
<lpage>4546</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0802864</pub-id>
<pub-id pub-id-type="pmid">20228200</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-21-00836">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Latzin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hordijk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Woischnik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krauss-Etschmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reinhardt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roscher</surname>
<given-names>A.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cleavage of cxcr1 on neutrophils disables bacterial killing in cystic fibrosis lung disease</article-title>
<source/>Nat. Med.
          <year>2007</year>
<volume>13</volume>
<fpage>1423</fpage>
<lpage>1430</lpage>
<pub-id pub-id-type="doi">10.1038/nm1690</pub-id>
<pub-id pub-id-type="pmid">18059279</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-21-00836">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Neville</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wroge</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Low serum alpha-1 antitrypsin (aat) in family members of individuals with autism correlates with pimz genotype</article-title>
<source/>Biomark Insights
          <year>2009</year>
<volume>4</volume>
<fpage>45</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.4137/BMI.S1115</pub-id>
<pub-id pub-id-type="pmid">19652762</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-21-00836">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rafeeq</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Murad</surname>
<given-names>H.A.S.</given-names>
</name>
</person-group>
<article-title>Cystic fibrosis: Current therapeutic targets and future approaches</article-title>
<source/>J. Transl. Med.
          <year>2017</year>
<volume>15</volume>
<fpage>84</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-017-1193-9</pub-id>
<pub-id pub-id-type="pmid">28449677</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-21-00836">
<label>86.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>R.H.</given-names>
</name>
</person-group>
<article-title>Cystic fibrosis: Overview of the Treatment of Lung Disease. UpToDate: 2019</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/cystic-fibrosis-overview-of-the-treatment-of-lung-disease">https://www.uptodate.com/contents/cystic-fibrosis-overview-of-the-treatment-of-lung-disease</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-07-25">(accessed on 25 July 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B87-ijms-21-00836">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKelvey</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McAuley</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Taggart</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Targeting proteases in cystic fibrosis lung disease. Paradigms, progress, and potential</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2020</year>
<volume>201</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201906-1190PP</pub-id>
<pub-id pub-id-type="pmid">31626562</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-21-00836">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Latzin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kappler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weckerle</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Heinzlmaier</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bernhardt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hartl</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients</article-title>
<source/>Eur. Respir. J.
          <year>2007</year>
<volume>29</volume>
<fpage>240</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1183/09031936.00047306</pub-id>
<pub-id pub-id-type="pmid">17050563</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-21-00836">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Downey</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bilton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Keogan</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis</article-title>
<source/>Pediatric Pulmonol.
          <year>2006</year>
<volume>41</volume>
<fpage>177</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1002/ppul.20345</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-21-00836">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Cantin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cooley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Remold-O’Donnell</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Aerosol treatment with mnei suppresses bacterial proliferation in a model of chronic pseudomonas aeruginosa lung infection</article-title>
<source/>Pediatric Pulmonol.
          <year>2005</year>
<volume>39</volume>
<fpage>141</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1002/ppul.20167</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-21-00836">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogelmeier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gillissen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buhl</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity</article-title>
<source/>Chest
          <year>1996</year>
<volume>110</volume>
<fpage>261s</fpage>
<lpage>266s</lpage>
<pub-id pub-id-type="doi">10.1378/chest.110.6_Supplement.261S</pub-id>
<pub-id pub-id-type="pmid">8989162</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-21-00836">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Birrer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Alphonso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Crystal</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor</article-title>
<source/>J. Clin. Investig.
          <year>1992</year>
<volume>90</volume>
<fpage>1296</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1172/JCI115994</pub-id>
<pub-id pub-id-type="pmid">1357002</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-21-00836">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Small</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Zani</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Dallet-Choisy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Glasgow</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>O’Kane</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McAuley</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation</article-title>
<source/>Mol. Ther.
          <year>2015</year>
<volume>23</volume>
<fpage>24</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1038/mt.2014.162</pub-id>
<pub-id pub-id-type="pmid">25189740</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-21-00836">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camper</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Glasgow</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Osbourn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Lundy</surname>
<given-names>F.T.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>R.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A secretory leukocyte protease inhibitor variant with improved activity against lung infection</article-title>
<source/>Mucosal Immunol.
          <year>2016</year>
<volume>9</volume>
<fpage>669</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.1038/mi.2015.90</pub-id>
<pub-id pub-id-type="pmid">26376365</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-21-00836">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polverino</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rosales-Mayor</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Dembowsky</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The role of neutrophil elastase inhibitors in lung diseases</article-title>
<source/>Chest
          <year>2017</year>
<volume>152</volume>
<fpage>249</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/j.chest.2017.03.056</pub-id>
<pub-id pub-id-type="pmid">28442313</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-21-00836">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunlevy</surname>
<given-names>F.K.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>de Courcey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Ennis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory effects of dx-890, a human neutrophil elastase inhibitor</article-title>
<source/>J. Cyst. Fibros.
          <year>2012</year>
<volume>11</volume>
<fpage>300</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcf.2012.02.003</pub-id>
<pub-id pub-id-type="pmid">22418019</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-21-00836">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chillappagari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mahavadi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Guenther</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nährlich</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rosenblum</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Henke</surname>
<given-names>M.O.</given-names>
</name>
</person-group>
<article-title>A small molecule neutrophil elastase inhibitor, krp-109, inhibits cystic fibrosis mucin degradation</article-title>
<source/>J. Cyst. Fibros.
          <year>2016</year>
<volume>15</volume>
<fpage>325</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcf.2015.10.008</pub-id>
<pub-id pub-id-type="pmid">26526358</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-21-00836">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yanagihara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Morinaga</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Izumikawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kakeya</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kohno</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo efficacy of krp-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia</article-title>
<source/>Pulm. Pharmacol. Ther.
          <year>2011</year>
<volume>24</volume>
<fpage>660</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="doi">10.1016/j.pupt.2011.08.001</pub-id>
<pub-id pub-id-type="pmid">21864700</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-21-00836">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Perrett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Forsman-Semb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marks-Konczalik</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gunawardena</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Entwistle</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Efficacy, safety and effect on biomarkers of azd9668 in cystic fibrosis</article-title>
<source/>Eur. Respir. J.
          <year>2012</year>
<volume>40</volume>
<fpage>969</fpage>
<pub-id pub-id-type="doi">10.1183/09031936.00194611</pub-id>
<pub-id pub-id-type="pmid">22267768</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-21-00836">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kummarapurugu</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Afosah</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Sankaranarayanan</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Navaz Gangji</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Voynow</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>U.R.</given-names>
</name>
</person-group>
<article-title>Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>12480</fpage>
<lpage>12490</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA118.002644</pub-id>
<pub-id pub-id-type="pmid">29903912</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-21-00836">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Argyle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Prechel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prestwich</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Hoidal</surname>
<given-names>J.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of rage with its ligands</article-title>
<source/>Am. J. Physiol. Cell Physiol.
          <year>2010</year>
<volume>299</volume>
<fpage>C97</fpage>
<lpage>C110</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00009.2010</pub-id>
<pub-id pub-id-type="pmid">20375277</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-21-00836">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craciun</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fenner</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Kerns</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>N-arylacyl o-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin g and proteinase 3</article-title>
<source/>Glycobiology
          <year>2016</year>
<volume>26</volume>
<fpage>701</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1093/glycob/cww011</pub-id>
<pub-id pub-id-type="pmid">26850997</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-21-00836">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Abdalla</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bratcher</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Sabbatini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Blalock</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>J.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Doxycycline improves clinical outcomes during cystic fibrosis exacerbations</article-title>
<source/>Eur. Respir. J.
          <year>2017</year>
<volume>49</volume>
<pub-id pub-id-type="doi">10.1183/13993003.01102-2016</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-21-00836">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantin</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Berthiaume</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cloutier</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Prolastin aerosol therapy and sputum taurine in cystic fibrosis</article-title>
<source/>Clin. Investig. Med. Med. Clin. Exp.
          <year>2006</year>
<volume>29</volume>
<fpage>201</fpage>
<lpage>207</lpage>
</element-citation>
</ref>
<ref id="B105-ijms-21-00836">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wozniak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wandtke</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kopinski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chorostowska-Wynimko</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Challenges and prospects for alpha-1 antitrypsin deficiency gene therapy</article-title>
<source/>Hum.Gene Ther.
          <year>2015</year>
<volume>26</volume>
<fpage>709</fpage>
<lpage>718</lpage>
<pub-id pub-id-type="doi">10.1089/hum.2015.044</pub-id>
<pub-id pub-id-type="pmid">26413996</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-21-00836">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Baley</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rothenberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leland</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ponder</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Finegold</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Darlington</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pokorny</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1992</year>
<volume>89</volume>
<fpage>89</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.89.1.89</pub-id>
<pub-id pub-id-type="pmid">1729724</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-21-00836">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hacein-Bey-Abina</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garrigue</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Soulier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morillon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Clappier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Caccavelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Delabesse</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beldjord</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of scid-x1</article-title>
<source/>J. Clin. Investig.
          <year>2008</year>
<volume>118</volume>
<fpage>3132</fpage>
<lpage>3142</lpage>
<pub-id pub-id-type="doi">10.1172/JCI35700</pub-id>
<pub-id pub-id-type="pmid">18688285</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-21-00836">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Nazir</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Metcalf</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Implications of the innate immune response to adenovirus and adenoviral vectors</article-title>
<source/>Future Virol.
          <year>2011</year>
<volume>6</volume>
<fpage>357</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="doi">10.2217/fvl.11.6</pub-id>
<pub-id pub-id-type="pmid">21738557</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-21-00836">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbashir</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Patkaniowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lendeckel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tuschl</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Functional anatomy of sirnas for mediating efficient rnai in drosophila melanogaster embryo lysate</article-title>
<source/>EMBO J.
          <year>2001</year>
<volume>20</volume>
<fpage>6877</fpage>
<lpage>6888</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/20.23.6877</pub-id>
<pub-id pub-id-type="pmid">11726523</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-21-00836">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gruntman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blomenkamp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Teckman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zamore</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Flotte</surname>
<given-names>T.R.</given-names>
</name>
</person-group>
<article-title>Sustained mirna-mediated knockdown of mutant aat with simultaneous augmentation of wild-type aat has minimal effect on global liver mirna profiles</article-title>
<source/>Mol. Ther.
          <year>2012</year>
<volume>20</volume>
<fpage>590</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1038/mt.2011.292</pub-id>
<pub-id pub-id-type="pmid">22252449</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-21-00836">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rana</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Illuminating the silence: Understanding the structure and function of small rnas</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2007</year>
<volume>8</volume>
<fpage>23</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2085</pub-id>
<pub-id pub-id-type="pmid">17183358</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-21-00836">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartel</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Micrornas: Genomics, biogenesis, mechanism, and function</article-title>
<source/>Cell
          <year>2004</year>
<volume>116</volume>
<fpage>281</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id>
<pub-id pub-id-type="pmid">14744438</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-21-00836">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lytle</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Yario</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Steitz</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Target mrnas are repressed as efficiently by microrna-binding sites in the 5’ utr as in the 3’ utr</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>9667</fpage>
<lpage>9672</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0703820104</pub-id>
<pub-id pub-id-type="pmid">17535905</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-21-00836">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Feinbaum</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Ambros</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The c. Elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14</article-title>
<source/>Cell
          <year>1993</year>
<volume>75</volume>
<fpage>843</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(93)90529-Y</pub-id>
<pub-id pub-id-type="pmid">8252621</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-21-00836">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKiernan</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Microrna dysregulation in cystic fibrosis</article-title>
<source/>Mediat. Inflamm.
          <year>2015</year>
<volume>2015</volume>
<fpage>529642</fpage>
<pub-id pub-id-type="doi">10.1155/2015/529642</pub-id>
<pub-id pub-id-type="pmid">26185362</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-21-00836">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Chiou</surname>
<given-names>G.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Chiou</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Microrna and aging: A novel modulator in regulating the aging network</article-title>
<source/>Ageing Res. Rev.
          <year>2010</year>
<volume>9</volume>
<issue>Suppl. S1</issue>
<fpage>S59</fpage>
<lpage>S66</lpage>
<pub-id pub-id-type="doi">10.1016/j.arr.2010.08.002</pub-id>
<pub-id pub-id-type="pmid">20708718</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-21-00836">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Microrna biogenesis pathway genes polymorphisms and cancer risk: A systematic review and meta-analysis</article-title>
<source/>PeerJ
          <year>2016</year>
<volume>4</volume>
<fpage>e2706</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.2706</pub-id>
<pub-id pub-id-type="pmid">27957388</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-21-00836">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>The microrna-21 in autoimmune diseases</article-title>
<source/>Int. J. Mol. Sci.
          <year>2016</year>
<volume>17</volume>
<elocation-id>864</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms17060864</pub-id>
<pub-id pub-id-type="pmid">27271606</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-21-00836">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumann</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Mirna-based therapies: Strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents</article-title>
<source/>Future Med. Chem.
          <year>2014</year>
<volume>6</volume>
<fpage>1967</fpage>
<lpage>1984</lpage>
<pub-id pub-id-type="doi">10.4155/fmc.14.116</pub-id>
<pub-id pub-id-type="pmid">25495987</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-21-00836">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenvang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Petri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lindow</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Obad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kauppinen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Inhibition of microrna function by antimir oligonucleotides</article-title>
<source/>Silence
          <year>2012</year>
<volume>3</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1186/1758-907X-3-1</pub-id>
<pub-id pub-id-type="pmid">22230293</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-21-00836">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillen</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Gosalia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leir</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Microrna regulation of expression of the cystic fibrosis transmembrane conductance regulator gene</article-title>
<source/>Biochem. J.
          <year>2011</year>
<volume>438</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20110672</pub-id>
<pub-id pub-id-type="pmid">21689072</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-21-00836">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Chotirmall</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Regulation of cystic fibrosis transmembrane conductance regulator by microrna-145, -223, and -494 is altered in deltaf508 cystic fibrosis airway epithelium</article-title>
<source/>J. Immunol.
          <year>2013</year>
<volume>190</volume>
<fpage>3354</fpage>
<lpage>3362</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1202960</pub-id>
<pub-id pub-id-type="pmid">23436935</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-21-00836">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karp</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wohlford-Lenane</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lennox</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Jacobi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Praekh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Behlke</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by micrornas</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>2013</year>
<volume>49</volume>
<fpage>544</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2012-0430OC</pub-id>
<pub-id pub-id-type="pmid">23646886</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-21-00836">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Seia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Elce</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zarrilli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Castaldo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tomaiuolo</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Gene mutation in microrna target sites of cftr gene: A novel pathogenetic mechanism in cystic fibrosis?</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e60448</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0060448</pub-id>
<pub-id pub-id-type="pmid">23555973</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-21-00836">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karp</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ostedgaard</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Walz</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Keshavjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lennox</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Jacobi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A microrna network regulates expression and biosynthesis of wild-type and deltaf508 mutant cystic fibrosis transmembrane conductance regulator</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2012</year>
<volume>109</volume>
<fpage>13362</fpage>
<lpage>13367</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1210906109</pub-id>
<pub-id pub-id-type="pmid">22853952</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-21-00836">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruffin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Voland</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Blouquit-Laye</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Naline</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Puyo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Le Rouzic</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Guillot</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anoctamin 1 dysregulation alters bronchial epithelial repair in cystic fibrosis</article-title>
<source/>Biochim. Biophys. Acta
          <year>2013</year>
<volume>1832</volume>
<fpage>2340</fpage>
<lpage>2351</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2013.09.012</pub-id>
<pub-id pub-id-type="pmid">24080196</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-21-00836">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonneville</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruffin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coraux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rousselet</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Le Rouzic</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Blouquit-Laye</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tabary</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Microrna-9 downregulates the ano1 chloride channel and contributes to cystic fibrosis lung pathology</article-title>
<source/>Nat. Commun.
          <year>2017</year>
<volume>8</volume>
<fpage>710</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-00813-z</pub-id>
<pub-id pub-id-type="pmid">28955034</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-21-00836">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Chotirmall</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Stallings</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Mir-126 is downregulated in cystic fibrosis airway epithelial cells and regulates tom1 expression</article-title>
<source/>J. Immunol.
          <year>2010</year>
<volume>184</volume>
<fpage>1702</fpage>
<lpage>1709</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0902669</pub-id>
<pub-id pub-id-type="pmid">20083669</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-21-00836">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.X.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Koff</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bruscia</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Pharmacological modulation of the akt/microrna-199a-5p/cav1 pathway ameliorates cystic fibrosis lung hyper-inflammation</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>6221</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms7221</pub-id>
<pub-id pub-id-type="pmid">25665524</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-21-00836">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Vencken</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gaughan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Molloy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Mir-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production</article-title>
<source/>Eur. Respir. J.
          <year>2015</year>
<volume>46</volume>
<fpage>1350</fpage>
<lpage>1360</lpage>
<pub-id pub-id-type="doi">10.1183/09031936.00163414</pub-id>
<pub-id pub-id-type="pmid">26160865</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-21-00836">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbri</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Borgatti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montagner</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Finotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lampronti</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bezzerri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dechecchi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Cabrini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gambari</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Expression of microrna-93 and interleukin-8 during pseudomonas aeruginosa-mediated induction of proinflammatory responses</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>2014</year>
<volume>50</volume>
<fpage>1144</fpage>
<lpage>1155</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2013-0160OC</pub-id>
<pub-id pub-id-type="pmid">24433094</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-21-00836">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhattacharyya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Balakathiresan</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Dalgard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gutti</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Armistead</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jozwik</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Elevated mir-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8</article-title>
<source/>J. Biol. Chem.
          <year>2011</year>
<volume>286</volume>
<fpage>11604</fpage>
<lpage>11615</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.198390</pub-id>
<pub-id pub-id-type="pmid">21282106</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-21-00836">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luly</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Leveque</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Licursi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cimino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Martin-Chouly</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Theret</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cavinato</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ascenzioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Del Porto</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Mir-146a is over-expressed and controls il-6 production in cystic fibrosis macrophages</article-title>
<source/>Sci. Rep.
          <year>2019</year>
<volume>9</volume>
<fpage>16259</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-019-52770-w</pub-id>
<pub-id pub-id-type="pmid">31700158</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-21-00836">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tazi</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Dakhlallah</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Caution</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Khalil</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kopp</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated mirc1/mir17-92 cluster expression negatively regulates autophagy and cftr (cystic fibrosis transmembrane conductance regulator) function in cf macrophages</article-title>
<source/>Autophagy
          <year>2016</year>
<volume>12</volume>
<fpage>2026</fpage>
<lpage>2037</lpage>
<pub-id pub-id-type="doi">10.1080/15548627.2016.1217370</pub-id>
<pub-id pub-id-type="pmid">27541364</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-21-00836">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierdomenico</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Patruno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Codagnone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simiele</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mari</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Plebani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Recchiuti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Microrna-181b is increased in cystic fibrosis cells and impairs lipoxin a4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>13519</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-14055-y</pub-id>
<pub-id pub-id-type="pmid">29044225</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-21-00836">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchiya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalurupalle</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ghoshal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lehrmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Gorospe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Rptor, a novel target of mir-155, elicits a fibrotic phenotype of cystic fibrosis lung epithelium by upregulating ctgf</article-title>
<source/>RNA Biol.
          <year>2016</year>
<volume>13</volume>
<fpage>837</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="doi">10.1080/15476286.2016.1197484</pub-id>
<pub-id pub-id-type="pmid">27284727</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-21-00836">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weldon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>McAuley</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Wohlford-Lenane</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Mir-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin s production</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2014</year>
<volume>190</volume>
<fpage>165</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201311-1986OC</pub-id>
<pub-id pub-id-type="pmid">24940638</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-21-00836">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Mirna-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of atf6</article-title>
<source/>Mol. Cell. Pediatrics
          <year>2015</year>
<volume>2</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/s40348-014-0012-0</pub-id>
<pub-id pub-id-type="pmid">26542291</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-21-00836">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glasgow</surname>
<given-names>A.M.A.</given-names>
</name>
<name>
<surname>De Santi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Non-coding rna in cystic fibrosis</article-title>
<source/>Biochem. Soc. Trans.
          <year>2018</year>
<volume>46</volume>
<fpage>619</fpage>
<lpage>630</lpage>
<pub-id pub-id-type="doi">10.1042/BST20170469</pub-id>
<pub-id pub-id-type="pmid">29743276</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-21-00836">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dutta</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Chinnapaiyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Unwalla</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Aberrant micrornaomics in pulmonary complications: Implications in lung health and diseases</article-title>
<source/>Mol. Ther. Nucleic Acids
          <year>2019</year>
<volume>18</volume>
<fpage>413</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1016/j.omtn.2019.09.007</pub-id>
<pub-id pub-id-type="pmid">31655261</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-21-00836">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>McKiernan</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Therapeutic modulation of mirna for the treatment of proinflammatory lung diseases</article-title>
<source/>Expert Rev. Anti-Infect. Ther.
          <year>2012</year>
<volume>10</volume>
<fpage>359</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.1586/eri.11.175</pub-id>
<pub-id pub-id-type="pmid">22397568</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-21-00836">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Zandwijk</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pavlakis</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Linton</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huynh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chrzanowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fulham</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>D.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety and activity of microrna-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study</article-title>
<source/>Lancet. Oncol.
          <year>2017</year>
<volume>18</volume>
<fpage>1386</fpage>
<lpage>1396</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30621-6</pub-id>
<pub-id pub-id-type="pmid">28870611</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-21-00836">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Gaughan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Oglesby</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Isolation and identification of cell-specific micrornas targeting a messenger rna using a biotinylated anti-sense oligonucleotide capture affinity technique</article-title>
<source/>Nucleic Acids Res.
          <year>2013</year>
<volume>41</volume>
<fpage>e71</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gks1466</pub-id>
<pub-id pub-id-type="pmid">23325846</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-21-00836-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Neutrophil elastase (NE) has a wide range of effects including: (1) cleavage of other proteases/antiproteases; (2) cleavage of antimicrobial peptides (AMPs); (3) cleavage of flagellin; (4) cleavage of opsonizing peptides; (5) cleavage of cell surface receptors; (6) neutrophil extracellular trap (NET) formation; (7) upregulation of pro-inflammatory cytokines; (8) upregulation of mucin genes; (9) impairing ciliary function; (10) degradation of extracellular matrix (ECM) proteins.</p>
</caption>
<graphic xlink:href="ijms-21-00836-g001"></graphic>
</fig>
<table-wrap id="ijms-21-00836-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-00836-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Antiprotease therapies in cystic fibrosis (CF).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Therapy</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Main Findings</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Study(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>A1AT Augmentation Therapies</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intravenous A1AT</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transiently suppressed the effects of NE in the lungs of CF patients</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">McElvaney, et al. [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Inhaled, aerosolised A1AT</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibited NE in the respiratory epithelium of CF patients (if A1AT BALF levels reached &gt;8 µM)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">McElvaney et al. [<xref ref-type="bibr" rid="B58-ijms-21-00836">58</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Administration to CF patients did not substantially decrease anti-NE activity in induced sputum samples</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cantin et al. [<xref ref-type="bibr" rid="B104-ijms-21-00836">104</xref>]</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Recombinant Antiproteases</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Recombinant A1AT (rA1AT)</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Administration to CF patients reduced NE/A1AT complex and sputum MPO levels; downward trend of NE activity in sputum did not reach statistical significance</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Martin et al. [<xref ref-type="bibr" rid="B89-ijms-21-00836">89</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Recombinant SLPI (rSLPI)</td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Increased anti-NE activity in the lungs of CF patients;<break></break>Enhanced antioxidant protection in sheep lung models by raising glutathione levels </td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Vogelmeier et al. [<xref ref-type="bibr" rid="B91-ijms-21-00836">91</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Significantly reduced active NE, IL-8 and neutrophil number in epithelial lining fluid (ELF) </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">McElvaney et al. [<xref ref-type="bibr" rid="B92-ijms-21-00836">92</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Recombinant hMNEI</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Significantly reduced inflammatory injury in murine models of <italic>P. aeruginosa</italic> infection; significantly enhanced bacterial clearance in <italic>P. aeruginosa</italic> infected rat lungs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Woods et al. [<xref ref-type="bibr" rid="B90-ijms-21-00836">90</xref>]</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Antiprotease Functional Variants</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elafin functional variants <break></break>(“GG”- and “QQ”-elafin)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Both variants showed increased resistance to degradation when incubated with BALF from CF patients. GG-elafin showed enhanced LPS neutralisation in vitro, and decreased inflammatory cell infiltration in a murine model of acute lung injury. The latter was associated with a reduction in monocyte chemoattractant protein-1 (MCP-1).</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Small et al. [<xref ref-type="bibr" rid="B93-ijms-21-00836">93</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLPI functional variants (“SLPI-A16G” and “SLPI-S15G-A16G”)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Both variants showed enhanced resistance to degradation when incubated with sputum from CF patients. SLPI-A16G demonstrated increased anti-inflammatory activity in a murine model of <italic>P. aeruginosa</italic> infection.</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Camper et al. [<xref ref-type="bibr" rid="B94-ijms-21-00836">94</xref>]</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Synthetic Protease Inhibitors</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">POL6014</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Significantly reduces NE activity without impairing neutrophil function</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Polverino et al. [<xref ref-type="bibr" rid="B95-ijms-21-00836">95</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DX-890</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreases pro-inflammatory cytokine secretion and neutrophil transmigration</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dunlevy et al. [<xref ref-type="bibr" rid="B96-ijms-21-00836">96</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">KRP-109</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">May reverse mucus plugging in CF airways by decreasing NE-prompted mucin degradation</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chillappagari et al. [<xref ref-type="bibr" rid="B97-ijms-21-00836">97</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No difference in BALF NE activity between KRP-109-treated murine pneumococcal models and controls, however KRP-109-treated mice had higher survival rates and reduced alveolar inflammation</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yamada et al. [<xref ref-type="bibr" rid="B98-ijms-21-00836">98</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AZD9688</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced free and total urinary desmosine (biomarkers of elastin degradation), but no observable differences in sputum, NE activity, lung function, respiratory symptoms, or use of reliever medication</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elborn et al. [<xref ref-type="bibr" rid="B99-ijms-21-00836">99</xref>]</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Modified Drugs and Pre-Existing Drugs</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">2-<italic>O</italic>, 3-<italic>O</italic>-desulfated heparin (ODSH)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ODSH are ineffective in CF sputum in the absence of dornase α (recombinant DNase), as ODSH and DNA compete for NE binding sites. ODSH have a higher potency of NE inhibition than DNA.</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kummarapurugu et al. [<xref ref-type="bibr" rid="B100-ijms-21-00836">100</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The 2-O and 3-O sulfate groups on heparin can be removed to reduce its anticoagulant activity without impairing its anti-inflammatory activity. ODSH inhibits, NE, CatG, complement activation and binding to P-selectin</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rao et al. [<xref ref-type="bibr" rid="B101-ijms-21-00836">101</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>N</italic>-Arylacyl <italic>O</italic>-sulfonated aminoglycosides<break></break>(KanCbz and NeoCbz)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">KanCbz inhibits NE, PR3 and CatG.<break></break>NeoCbz inhibits NE and CatG<break></break>Both KanCbz and NeoCbz protected respiratory epithelial cells from protease-mediated destruction</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Craciun et al. [<xref ref-type="bibr" rid="B102-ijms-21-00836">102</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Doxycycline</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Doxycycline significantly reduced sputum MMP-9 levels and was associated with a 1.6-fold increase in tissue inhibitor of metalloproteinase-1 (TIMP1) levels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Xu et al. [<xref ref-type="bibr" rid="B103-ijms-21-00836">103</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-00836-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-00836-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>The basis of miRNA-targeting therapeutic strategies.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Dysfunction</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Overabundant mRNA/Protein</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Lack of a mRNA/Protein</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Overexpressed MicroRNA</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Underexpressed MicroRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Strategy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">↑ microRNA(s)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">↓ microRNA(s)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">↓ microRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">↑ microRNA</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Method</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miRNA mimic(s)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Antagomir(s) or TSB(s)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Antagomir or TSB(s)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miRNA mimic</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>↑ = increase; ↓ = decrease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>